<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Manchester Pharmacy School</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8F4814A9-89E1-47D5-833A-B05FE493A7C5"><gtr:id>8F4814A9-89E1-47D5-833A-B05FE493A7C5</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Stratford</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2A923CFD-CC49-4104-B5C5-2F4D7B413C91"><gtr:id>2A923CFD-CC49-4104-B5C5-2F4D7B413C91</gtr:id><gtr:firstName>Rachel</gtr:firstName><gtr:surname>Cowen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9913E725-22A7-4182-8791-A27E3E57B4EB"><gtr:id>9913E725-22A7-4182-8791-A27E3E57B4EB</gtr:id><gtr:firstName>Kaye</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500366"><gtr:id>8EB20CE3-631F-41BF-9FB7-A67B37CB926B</gtr:id><gtr:title>Pre-clinical development of hypoxia-based strategies for cancer treatment.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500366</gtr:grantReference><gtr:abstractText>Hypoxic cells in tumours comprise a sub-population of cells that are resistant to radio-and chemotherapy. The greater the proportion of hypoxic cells in tumours the greater chance of resistance to therapy in the clinic and the bigger chance of the development of metastatic disease. The Stratford/Williams group are working towards understanding the mechanistic basis of these hypoxia-mediated processes. In achieving this they are identifying new molecular targets which can be used for drug therapy.

To achieve these objectives this group combines the expertise of medicinal chemistry and pharmacology with molecular, cell and tumour biology</gtr:abstractText><gtr:technicalSummary>The presence of hypoxic cells in tumours is a major barrier to cancer treatment. However, tumour hypoxia constitutes a unique physiological abnormality which can be exploited to develop more effective treatments. This research proposal seeks to develop novel hypoxia-mediated therapeutic approaches and the objectives of our research are:
* Gain an understanding of the underlying mechanisms by which Hypoxia Inducible Factor-1 (HIF-1) can influence tumour growth and response to radiation or chemotherapy. Then use this information to develop small molecule inhibitors of HIF.
* To determine whether downstream targets of HIF activity, such as Carbonic anhydrase IX (CAIX), VEGF or nitric oxide synthase (NOS) can be exploited for therapeutic benefit.
* Develop a platform technology for hypoxia-mediated bioreductive drug activation and delivery.
* Determine the roles of hypoxia and HIF in metastatic disease, and define the therapeutic role of bioreductive drugs in the treatment of metastases.
* To provide further information to validate the concept of hypoxia-mediated gene therapy for the treatment of solid tumours.
The overall goal of this translational research is to facilitate the introduction of new entities/modalities into cancer treatment.</gtr:technicalSummary><gtr:fund><gtr:end>2010-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1209871</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>cheo/radiotherapy clinician scientist PhD</gtr:description><gtr:id>20BC33FC-94D4-4386-9204-E355B59ADADE</gtr:id><gtr:impact>No out puts yet
Multidisciplinary: Clinical, pharmacology, tumour biology, radiobiology.</gtr:impact><gtr:outcomeId>Vjrdh56Vduj-1</gtr:outcomeId><gtr:partnerContribution>Clinical perspective</gtr:partnerContribution><gtr:piContribution>scientific input</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>chemo/radiotherapy interactions post-doc</gtr:description><gtr:id>68FA07B9-123C-4DF3-BF68-5AC08046EC29</gtr:id><gtr:impact>TWo clinical (MEERCAT and DREAM) trials about to start in Manchester based on this work: 17308057 18819995 19843666</gtr:impact><gtr:outcomeId>BFB617BECF4-1</gtr:outcomeId><gtr:partnerContribution>intellectual, reagents and facilities</gtr:partnerContribution><gtr:piContribution>expertise in radiobiology and pre-clinical models</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>chemo/radiotherapy MD</gtr:description><gtr:id>94AAA5B5-A7BC-4EA8-AD84-6BD3AA4D3FBA</gtr:id><gtr:impact>Development and execution of MEERCAT trial</gtr:impact><gtr:outcomeId>B404E65DD00-1</gtr:outcomeId><gtr:partnerContribution>intellectual</gtr:partnerContribution><gtr:piContribution>Expertise, in radiobiology, hypoxia and drug development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oncology</gtr:department><gtr:description>MCRC/Astrazeneca Alliance</gtr:description><gtr:id>3EFA50CA-EAF1-41CA-8BFC-22636888E033</gtr:id><gtr:impact>Published papers relevant to this partnership include:</gtr:impact><gtr:outcomeId>e4TWqVggJxg-1</gtr:outcomeId><gtr:partnerContribution>Provision of drugs and funding.</gtr:partnerContribution><gtr:piContribution>Development of drug radiation combinations for prospective clinical trial.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>8500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>pump-priming initiative</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>University of Manchester</gtr:fundingOrg><gtr:id>CEC6D4B2-2A77-4C3E-9C7A-3A874F2924C5</gtr:id><gtr:outcomeId>E716CD086520</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BCC Project Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Breast Cancer Campaign (BCC)</gtr:fundingOrg><gtr:id>DB53E873-6BDF-47A0-B56D-E7A45BBF5EE0</gtr:id><gtr:outcomeId>72F232254950</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>105000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>fully funded CR-UK PhD as support of Integrative Mammalian Biology (joiny reseach councils) Award &amp;pound;2.7M to University of Manchester</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>07ADB231-7EF8-4912-A681-E9833EF6CABA</gtr:id><gtr:outcomeId>2F860303A9A0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR Project Grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>E98EE681-9CC7-4116-B9F4-7BBF9CBAEE29</gtr:id><gtr:outcomeId>CZieE5BZwWR</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE Studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>792544FF-13FD-48DC-848D-96A43F805D2B</gtr:id><gtr:outcomeId>E33AFD128E50</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>175000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR Project Grant</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>8127CDE4-DA5D-4C95-B267-55B6F19EE15F</gtr:id><gtr:outcomeId>B9E7B8D56800</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>460000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EC FP7 funding</gtr:description><gtr:end>2008-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>4E498A60-4400-42BE-A33F-81EF1D771561</gtr:id><gtr:outcomeId>900E62586620</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>bbsrc case award</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>865B6E15-978F-427B-AC26-C170559BF7C6</gtr:id><gtr:outcomeId>tBmKn9Wxb9F0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant (new agents committee)</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>B9A83442-598D-43C0-9D9D-55C9C1895502</gtr:id><gtr:outcomeId>74938859A5E0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI clinical and translational radiotherapy research working group</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>70B38E59-760D-40A9-B733-DD59F250758A</gtr:id><gtr:impact>No deliverables as yet, but proposal is to influence capacity and training in radiotherapy; enhance basic and translational research related to radiotherapy; and deliver practice changing clinical trials</gtr:impact><gtr:outcomeId>CD6033A5548</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EORTC Executive</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>A4EF4063-4F72-44E7-A057-1C8D586568FE</gtr:id><gtr:impact>The impact of rationalizing European research in this way is to deliver more practice changing trials, such as the EORTC trial on radiotherapy combined with temozolamide in glioblastoma.</gtr:impact><gtr:outcomeId>2DD1D97BCA0</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>COMARE (Committee on Medical Effects of Radiation in the Environment)</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>53D52718-1B75-4A51-9D77-4A70D045BCFD</gtr:id><gtr:impact>Recent activity has been: Leukeamia incidence around atomic reactors. Indiscriminate use of sun beds Radon levels in the home Inappropriate use of asymptomatic whole body CAT scans</gtr:impact><gtr:outcomeId>F1FBE4D769A</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>131EB857-99B4-454D-BF79-C7907B9CCEFE</gtr:id><gtr:title>Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcea06ec65ff0679c17eaf0561024757"><gtr:id>fcea06ec65ff0679c17eaf0561024757</gtr:id><gtr:otherNames>Nolan KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>1399FAD6474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>322CA664-E805-4041-8CD4-3BB387411EE9</gtr:id><gtr:title>Cytotoxic properties of a 4-nitroimidazole (NSC 38087): a radiosensitizer of hypoxic cells in vitro.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1981-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7259957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7DC3A68-10AA-476C-A7F7-078071ECEE54</gtr:id><gtr:title>Some factors affecting the specific toxicity of misonidazole towards hypoxic mammalian cells.</gtr:title><gtr:parentPublicationTitle>The British journal of cancer. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1978-01-01</gtr:date><gtr:issn>0306-9443</gtr:issn><gtr:outcomeId>pm_14036_2036_277212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A07261F6-84BB-44EF-AD69-FAA43D3F5291</gtr:id><gtr:title>Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/782c336ca9b82847685504c7a7765613"><gtr:id>782c336ca9b82847685504c7a7765613</gtr:id><gtr:otherNames>Patterson AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>pm_14036_16_12085243</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C41E3ABF-543C-4098-AD45-21DFF2427202</gtr:id><gtr:title>The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab537111ebb08f745da671322d3314c3"><gtr:id>ab537111ebb08f745da671322d3314c3</gtr:id><gtr:otherNames>Megarity CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>pm_540e140e140b3e037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28DB1637-844F-4587-828C-CE604BAF3292</gtr:id><gtr:title>GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/969ca5ae814248b666d6e3479f9a68dc"><gtr:id>969ca5ae814248b666d6e3479f9a68dc</gtr:id><gtr:otherNames>Airley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>pm_14036_16_12532423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEA329B6-E3D1-40D7-96CD-27FC161917BA</gtr:id><gtr:title>Chemopotentiation by CB 1954: the importance of postincubations and the possible involvement of poly(ADP-ribosylation).</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5ca56685283bdb73fae9518c0f514b7"><gtr:id>d5ca56685283bdb73fae9518c0f514b7</gtr:id><gtr:otherNames>Walling JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1984-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_636_6434498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8E94B2B-A16B-43A0-9CEE-4770E5483317</gtr:id><gtr:title>Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dddfdaf440109f7e232cca893849617"><gtr:id>9dddfdaf440109f7e232cca893849617</gtr:id><gtr:otherNames>Ali M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>4EE6E3164AB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3776D9D-135F-4612-BE21-2A7984915575</gtr:id><gtr:title>Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/487986200aa81b294de6e6dd82fbed9d"><gtr:id>487986200aa81b294de6e6dd82fbed9d</gtr:id><gtr:otherNames>Phillips RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_16_10514277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4ECA617F-AC15-4C5C-9E98-F86A32F07510</gtr:id><gtr:title>Bioreductive drugs in cancer therapy.</gtr:title><gtr:parentPublicationTitle>BJR supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0961-2653</gtr:issn><gtr:outcomeId>pm_14036_136_1341908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E4279BB-389A-4E59-BA91-7C276627A630</gtr:id><gtr:title>Radiosensitization of mammalian cells by transition metal complexes containing nitroimidazole ligands.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8adfbdf41897f898a7cf41a14a7b9ac"><gtr:id>d8adfbdf41897f898a7cf41a14a7b9ac</gtr:id><gtr:otherNames>Chibber R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1984-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_636_6547935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA72E085-2F9F-49B3-A692-C548FBB6B2B5</gtr:id><gtr:title>Exogenous and endogenous markers of tumour oxygenation status: definitive markers of tumour hypoxia?</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3933f2c467c3c3aa83c6cc0807029139"><gtr:id>3933f2c467c3c3aa83c6cc0807029139</gtr:id><gtr:otherNames>Williams KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>pm_14036_16_16594164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A53C83C7-B0AF-4C57-8F99-07450831A582</gtr:id><gtr:title>The effect of hypoxia on acquired drug resistance and response to epidermal growth factor in Chinese hamster lung fibroblasts and human breast-cancer cells in vitro.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94035c6a0cfd6c8d6328c05bd245e9c2"><gtr:id>94035c6a0cfd6c8d6328c05bd245e9c2</gtr:id><gtr:otherNames>Kalra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>pm_14036_836_8514457</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4E7CD98-C814-4385-8678-2E0847585AC8</gtr:id><gtr:title>Targeting hypoxia with a new generation of indolequinones.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea87cc2fa9fe5edc388a4f4b5afb23ac"><gtr:id>ea87cc2fa9fe5edc388a4f4b5afb23ac</gtr:id><gtr:otherNames>Jaffar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1998-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_936_9755720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3E3EA3D-CC4A-4BCD-954D-742F98125523</gtr:id><gtr:title>Magnetic resonance spectroscopic studies on 'real-time' changes in RIF-1 tumour metabolism and blood flow during and after photodynamic therapy.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5761caa6a3ab1eecf3e9084b41e5e26f"><gtr:id>5761caa6a3ab1eecf3e9084b41e5e26f</gtr:id><gtr:otherNames>Bremner JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_836_8198974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C04F19C5-996D-4BF1-8341-021DF3A73F8B</gtr:id><gtr:title>The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/782c336ca9b82847685504c7a7765613"><gtr:id>782c336ca9b82847685504c7a7765613</gtr:id><gtr:otherNames>Patterson AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_836_8195035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82E1BE21-AE18-495D-BA66-05F16A3DF1BC</gtr:id><gtr:title>Hypoxia response elements.</gtr:title><gtr:parentPublicationTitle>Oncology research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5708cf68bc357243daa04696ca0af34f"><gtr:id>5708cf68bc357243daa04696ca0af34f</gtr:id><gtr:otherNames>O'Rourke JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0965-0407</gtr:issn><gtr:outcomeId>pm_14036_936_9406238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10D0CCFE-2A68-45C2-8C88-DB09B602A67B</gtr:id><gtr:title>Cytotoxicity of adriamycin on aerobic and hypoxic chinese hamster V79 cells in vitro.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189e6bc991e4a601e3505b421420837d"><gtr:id>189e6bc991e4a601e3505b421420837d</gtr:id><gtr:otherNames>Smith E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1980-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7437289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF5D3ECD-055A-4C51-A0BC-8E2A5334D8F5</gtr:id><gtr:title>Analogues of 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC) with anti-tumor properties.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b0f03b7be362959993efa2939ad5e3d"><gtr:id>1b0f03b7be362959993efa2939ad5e3d</gtr:id><gtr:otherNames>Arthurs CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>3A6443D5ACF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>111C3070-B82F-4CC6-A6E7-4C7EBE681347</gtr:id><gtr:title>Interaction of the cytotoxic and sensitizing effects of electron-affinic drugs and hyperthermia.</gtr:title><gtr:parentPublicationTitle>National Cancer Institute monograph</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0083-1921</gtr:issn><gtr:outcomeId>pm_14036_736_7177180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F0A25A9-20C5-43C9-8CE9-7B32F99997C5</gtr:id><gtr:title>NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/126fc3c1f8ddcb84da5f7324befc7942"><gtr:id>126fc3c1f8ddcb84da5f7324befc7942</gtr:id><gtr:otherNames>Saunders MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2000-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_16_10682679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BA0519F-A933-4256-A519-0E233F84B075</gtr:id><gtr:title>Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/782c336ca9b82847685504c7a7765613"><gtr:id>782c336ca9b82847685504c7a7765613</gtr:id><gtr:otherNames>Patterson AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1998-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_14036_936_9661884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD0CAF9D-392D-4997-87DE-FE1FE3730D17</gtr:id><gtr:title>Potential antitumour mitosenes: relationship between in vitro DNA interstrand cross-link formation and DNA damage in Escherichia coli K-12 strains.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7668af046d1701c27b0286a63a899f9d"><gtr:id>7668af046d1701c27b0286a63a899f9d</gtr:id><gtr:otherNames>Maliepaard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_14036_736_7945435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED541E9B-AF83-4E90-93DA-74C1DDB7B959</gtr:id><gtr:title>Spectrophotometric analysis of nucleic acids: oxygenation-dependent hyperchromism of DNA.</gtr:title><gtr:parentPublicationTitle>Analytical and bioanalytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/704e2affebee518be565193c810581f8"><gtr:id>704e2affebee518be565193c810581f8</gtr:id><gtr:otherNames>Doshi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1618-2642</gtr:issn><gtr:outcomeId>mn5ZsjoFqYp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>709B854E-D6EB-4304-83F5-4356F48F2335</gtr:id><gtr:title>Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5761caa6a3ab1eecf3e9084b41e5e26f"><gtr:id>5761caa6a3ab1eecf3e9084b41e5e26f</gtr:id><gtr:otherNames>Bremner JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_136_1457346</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9AD72C9-5F07-4C52-A376-EB00AE0AECF7</gtr:id><gtr:title>Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1.</gtr:title><gtr:parentPublicationTitle>The British journal of cancer. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1567bd194f9ae2f653b6c5c6fe08850"><gtr:id>b1567bd194f9ae2f653b6c5c6fe08850</gtr:id><gtr:otherNames>Wood PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0306-9443</gtr:issn><gtr:outcomeId>pm_14036_836_8763875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB4703D6-8AF3-4F93-A252-66A6E0325E39</gtr:id><gtr:title>The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e21660c1f7feca2b7fc0738ef9f9cf7"><gtr:id>5e21660c1f7feca2b7fc0738ef9f9cf7</gtr:id><gtr:otherNames>Chaplin DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1986-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_336_3755714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>494CF23D-E4BA-4F4E-B951-0CECF40EE11D</gtr:id><gtr:title>Enhancing effect of pre-treatment of cells with misonidazole in hypoxia on their response to melphalan in air.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189e6bc991e4a601e3505b421420837d"><gtr:id>189e6bc991e4a601e3505b421420837d</gtr:id><gtr:otherNames>Smith E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7104191</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61D8A64D-E0FF-461C-BAFF-AC462C45365B</gtr:id><gtr:title>Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d60fa6bf7fbb20b15a40b33e96d6a71f"><gtr:id>d60fa6bf7fbb20b15a40b33e96d6a71f</gtr:id><gtr:otherNames>Kirk J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7685615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A84B2C6-1286-4988-BF80-1EA2AD59D131</gtr:id><gtr:title>Enhancement of the cytotoxicity of radiosensitizers by modest hyperthermia: the electron-affinity relationship.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5ed41c10c67d923e19464612841d744"><gtr:id>b5ed41c10c67d923e19464612841d744</gtr:id><gtr:otherNames>Rajaratnam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7150485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9423D4E1-1FA2-4AD6-83E8-0165ADB3A214</gtr:id><gtr:title>Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/596e6f4d9dfba5418ae9136b8e0f0290"><gtr:id>596e6f4d9dfba5418ae9136b8e0f0290</gtr:id><gtr:otherNames>H?pfl G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_14036_16_12019179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60FFEA26-469E-4849-8A02-79D51A8AEA5E</gtr:id><gtr:title>17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4a9ccb4a0f516a7af15edb98ac85735"><gtr:id>f4a9ccb4a0f516a7af15edb98ac85735</gtr:id><gtr:otherNames>Chinje EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_16_11857025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CF0CF3B-19C1-4EDA-87AE-CB22AE559DE4</gtr:id><gtr:title>In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3933f2c467c3c3aa83c6cc0807029139"><gtr:id>3933f2c467c3c3aa83c6cc0807029139</gtr:id><gtr:otherNames>Williams KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>1748F78FBDE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CD9553A-5469-4E88-AA7E-C6E37DD38F15</gtr:id><gtr:title>5-substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en- 1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea87cc2fa9fe5edc388a4f4b5afb23ac"><gtr:id>ea87cc2fa9fe5edc388a4f4b5afb23ac</gtr:id><gtr:otherNames>Jaffar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1998-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_936_9524554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>944C0B7A-BA5C-4DC9-98B1-774B8CAD3AAC</gtr:id><gtr:title>A biochemical method for assessing the neurotoxic effects of misonidazole in the rat.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b061f5c6b8438778a75119b67096a9a3"><gtr:id>b061f5c6b8438778a75119b67096a9a3</gtr:id><gtr:otherNames>Rose GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1980-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7459223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7FAE3CE-7A1D-42D6-93F7-F8285A2398D3</gtr:id><gtr:title>The effect of the radiosensitizer misonidazole on motor nerve conduction velocity in the mouse.</gtr:title><gtr:parentPublicationTitle>The British journal of cancer. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2417d47888dee19434dca33a8b76535f"><gtr:id>2417d47888dee19434dca33a8b76535f</gtr:id><gtr:otherNames>Hirst DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1978-01-01</gtr:date><gtr:issn>0306-9443</gtr:issn><gtr:outcomeId>pm_14036_2036_277237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61ED052B-4D88-49BF-8898-37D249842C87</gtr:id><gtr:title>Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4a9ccb4a0f516a7af15edb98ac85735"><gtr:id>f4a9ccb4a0f516a7af15edb98ac85735</gtr:id><gtr:otherNames>Chinje EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>pm_14036_16_12761334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C52A1037-005A-41AB-B4CA-610A73E0AB17</gtr:id><gtr:title>RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1986-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_14036_336_3753579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1398051D-33B3-484E-ACEE-60BB3AA99E39</gtr:id><gtr:title>Dual induction of the Epo-Egr-TNF-alpha- plasmid in hypoxic human colon adenocarcinoma produces tumor growth delay.</gtr:title><gtr:parentPublicationTitle>The American surgeon</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e58b0e407051108549a2cad9757a5e8"><gtr:id>8e58b0e407051108549a2cad9757a5e8</gtr:id><gtr:otherNames>Salloum RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0003-1348</gtr:issn><gtr:outcomeId>pm_14036_16_12575775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A6E2DAE-FF4C-472E-B3CE-460CA0F61E2B</gtr:id><gtr:title>The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_236_2495261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A429C8FE-145C-4DF8-8896-F3EE711C113F</gtr:id><gtr:title>Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3b8f8bd6b8756bc4a1f6b6a65cd7cc2"><gtr:id>f3b8f8bd6b8756bc4a1f6b6a65cd7cc2</gtr:id><gtr:otherNames>Threadgill MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1991-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_236_2066984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08BF68BE-D843-41F5-9620-BA5D6262582A</gtr:id><gtr:title>Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/487986200aa81b294de6e6dd82fbed9d"><gtr:id>487986200aa81b294de6e6dd82fbed9d</gtr:id><gtr:otherNames>Phillips RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_14036_16_15498501</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55F60804-A36C-43B4-A350-0FFD2997AF67</gtr:id><gtr:title>Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18ef8bbc07a03f9f0bbcf5b882fef4e9"><gtr:id>18ef8bbc07a03f9f0bbcf5b882fef4e9</gtr:id><gtr:otherNames>Maxwell PH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_14036_936_9223322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3EDDEE5-E03F-47DF-BFF6-25BD548719C2</gtr:id><gtr:title>Abnormal radiosensitizing and cytotoxic properties of ortho-substituted nitroimidazoles.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1983-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_636_6601069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B62938B0-02A2-4A2F-9E37-70004C7F0A94</gtr:id><gtr:title>Evidence for a non-thermal effect of ultrasound.</gtr:title><gtr:parentPublicationTitle>The British journal of cancer. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d755423b8d55bb6247e67fc4c1fcaed4"><gtr:id>d755423b8d55bb6247e67fc4c1fcaed4</gtr:id><gtr:otherNames>ter Haar GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0306-9443</gtr:issn><gtr:outcomeId>pm_14036_636_6950756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC97C435-03FE-4CA1-AE6E-D2076A1EE576</gtr:id><gtr:title>Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1979-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_3036_312783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>706A59F2-252F-45CF-9BD7-BAF0F65EF9DA</gtr:id><gtr:title>Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe5b324e59d9c2c7947f50b50e49a2a"><gtr:id>7fe5b324e59d9c2c7947f50b50e49a2a</gtr:id><gtr:otherNames>McNally VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>pm_14036_16_12052210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B16686BA-833F-40D3-9D3F-D8549E2EE149</gtr:id><gtr:title>Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1a87ff2bff75427786c240df3b36c7f"><gtr:id>a1a87ff2bff75427786c240df3b36c7f</gtr:id><gtr:otherNames>Robertson N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>pm_14036_736_7946565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D325CA01-2B8A-4885-843C-7ACB6AA75E6D</gtr:id><gtr:title>Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcea06ec65ff0679c17eaf0561024757"><gtr:id>fcea06ec65ff0679c17eaf0561024757</gtr:id><gtr:otherNames>Nolan KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>njhJNdv5XFh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>414519FE-2346-46CC-B9CC-0A46C1D3DCC0</gtr:id><gtr:title>Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fe9d6f80cc66cd68eba859a99c410ed"><gtr:id>6fe9d6f80cc66cd68eba859a99c410ed</gtr:id><gtr:otherNames>Edwards HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1991-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>pm_14036_136_1677997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2355E317-032D-43D0-86DE-5388488705CB</gtr:id><gtr:title>Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer.</gtr:title><gtr:parentPublicationTitle>BMC clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcdb71f607ab1658a8bcd56d5770ce5b"><gtr:id>fcdb71f607ab1658a8bcd56d5770ce5b</gtr:id><gtr:otherNames>Latif A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1472-6890</gtr:issn><gtr:outcomeId>5aa91f3974c6c6.68821643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63842B78-BFEA-47CC-AB25-3385B55B0E54</gtr:id><gtr:title>Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy.</gtr:title><gtr:parentPublicationTitle>The British journal of cancer. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25eff122ae111ee6f061a67904384f6c"><gtr:id>25eff122ae111ee6f061a67904384f6c</gtr:id><gtr:otherNames>Nordsmark M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0306-9443</gtr:issn><gtr:outcomeId>pm_14036_836_8763887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D955ED8-3A2B-43E7-B472-E0C0A9A3A2C4</gtr:id><gtr:title>Subharmonic emission as an indicator of ultrasonically-induced biological damage.</gtr:title><gtr:parentPublicationTitle>Ultrasound in medicine &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/353cf45e493641a0eccabf01b532ce55"><gtr:id>353cf45e493641a0eccabf01b532ce55</gtr:id><gtr:otherNames>Morton KI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1983-01-01</gtr:date><gtr:issn>0301-5629</gtr:issn><gtr:outcomeId>pm_14036_636_6670148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>397D379F-DDA4-473A-AE73-DB75E555229B</gtr:id><gtr:title>A similarity model for the human angiogenic factor, thymidine phosphorylase/platelet derived-endothelial cell growth factor.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22b06ec69d0137bb4a231178d116e464"><gtr:id>22b06ec69d0137bb4a231178d116e464</gtr:id><gtr:otherNames>Cole C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_16_10766296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>228BFD46-A622-4797-9BB8-F50974599312</gtr:id><gtr:title>Synthesis and biological activity of thiazolylindolequinones, analogues of the natural product BE 10988.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c92ff6ddb6acecd77b99c636b7b08a62"><gtr:id>c92ff6ddb6acecd77b99c636b7b08a62</gtr:id><gtr:otherNames>Moody CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1995-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_736_7699696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50C3F877-0A52-4B05-A448-33D13167F5E6</gtr:id><gtr:title>Radiosensitization by the 2,4-dinitro-5-aziridinyl benzamide CB 1954: a structure/activity study.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5ca56685283bdb73fae9518c0f514b7"><gtr:id>d5ca56685283bdb73fae9518c0f514b7</gtr:id><gtr:otherNames>Walling JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1987-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_336_3496308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0F0CC9E-6517-4B98-9A46-9A51EE4D13E3</gtr:id><gtr:title>Site and strain-specific variation in gut microbiota profiles and metabolism in experimental mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6791e01fdad459dc17a56c9fa0773278"><gtr:id>6791e01fdad459dc17a56c9fa0773278</gtr:id><gtr:otherNames>Friswell MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>YnEq2n1DBNA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6C135B0-03D1-45FC-9494-16BC99A9AF65</gtr:id><gtr:title>Hypoxia and oxidative stress. Tumour hypoxia--therapeutic considerations.</gtr:title><gtr:parentPublicationTitle>Breast cancer research : BCR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3933f2c467c3c3aa83c6cc0807029139"><gtr:id>3933f2c467c3c3aa83c6cc0807029139</gtr:id><gtr:otherNames>Williams KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2001-01-01</gtr:date><gtr:issn>1465-5411</gtr:issn><gtr:outcomeId>pm_14036_16_11597323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>521441F2-8711-4AED-8A34-395D415D7F93</gtr:id><gtr:title>Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers.</gtr:title><gtr:parentPublicationTitle>Radiation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1976-01-01</gtr:date><gtr:issn>0033-7587</gtr:issn><gtr:outcomeId>pm_14036_9036_940937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DAD9056-978F-44A9-B6FF-017BC55E3B07</gtr:id><gtr:title>Testing for hypoxia in forearm skin of patients with systemic sclerosis, assessed by pimonidazole.</gtr:title><gtr:parentPublicationTitle>The Journal of rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47fd9c4fca980640a0089fd3a25ae20a"><gtr:id>47fd9c4fca980640a0089fd3a25ae20a</gtr:id><gtr:otherNames>Herrick AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0315-162X</gtr:issn><gtr:outcomeId>Qj7XCW3N62T</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5E5E326-7628-460F-B9C2-F7A1237686B5</gtr:id><gtr:title>Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f50e66d5bcc0927516b9fb1f9a94a7f"><gtr:id>5f50e66d5bcc0927516b9fb1f9a94a7f</gtr:id><gtr:otherNames>Dovedi SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58c82a413fe542.54230430</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07C27F52-E4FA-4F56-8FFC-9AFBA5C94166</gtr:id><gtr:title>ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3933f2c467c3c3aa83c6cc0807029139"><gtr:id>3933f2c467c3c3aa83c6cc0807029139</gtr:id><gtr:otherNames>Williams KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_14036_16_15623642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F875F0C-531D-4A7A-81A5-F0BFC2E47303</gtr:id><gtr:title>Heterocyclic analogues of L-citrulline as inhibitors of the isoforms of nitric oxide synthase (NOS) and identification of N(delta)-(4,5-dihydrothiazol-2-yl)ornithine as a potent inhibitor.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d73869bf3be083d43defca6b00741b5"><gtr:id>4d73869bf3be083d43defca6b00741b5</gtr:id><gtr:otherNames>Ulhaq S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>pm_14036_16_10530926</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0912A909-1AAA-4147-90D8-42FB357EF535</gtr:id><gtr:title>Effects of some hypoxic cell radiosensitizers on the decay of potentially lethal oxygen-dependent damage in fully hydrated spores.</gtr:title><gtr:parentPublicationTitle>The British journal of cancer. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad466fefdb6b133b73572cd505352819"><gtr:id>ad466fefdb6b133b73572cd505352819</gtr:id><gtr:otherNames>Tallentire A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1978-01-01</gtr:date><gtr:issn>0306-9443</gtr:issn><gtr:outcomeId>pm_14036_94036_98174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E7B16F7-1B4E-4E92-9056-23D27900022D</gtr:id><gtr:title>Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro.</gtr:title><gtr:parentPublicationTitle>Drug design and discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ece4fc336f814cb4f7184b3ffa4e9ff"><gtr:id>5ece4fc336f814cb4f7184b3ffa4e9ff</gtr:id><gtr:otherNames>Naylor MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>1026-7921</gtr:issn><gtr:outcomeId>pm_14036_836_8268395</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA5125F0-4591-4752-A2A0-6973BA3F4950</gtr:id><gtr:title>31P MRS to monitor the induction of tumor hypoxia by the modification of the oxygen affinity of hemoglobin using BW 589C.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94035c6a0cfd6c8d6328c05bd245e9c2"><gtr:id>94035c6a0cfd6c8d6328c05bd245e9c2</gtr:id><gtr:otherNames>Kalra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_836_8195020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56426721-2D18-4EEB-89F2-CA2873BB78A2</gtr:id><gtr:title>Reduction of tumour intracellular pH and enhancement of melphalan cytotoxicity by the ionophore Nigericin.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1567bd194f9ae2f653b6c5c6fe08850"><gtr:id>b1567bd194f9ae2f653b6c5c6fe08850</gtr:id><gtr:otherNames>Wood PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1995-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>pm_14036_736_7829226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4B87FAE-06FB-4DBF-9CAC-994F8A908387</gtr:id><gtr:title>Non-aqueous liquids as modifiers of lethal damage induced by Bacillus megaterium spores by gamma-rays.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1972-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn><gtr:outcomeId>pm_14036_436_4144847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5702CE8-BA7F-4F83-9316-7B6044B20D0A</gtr:id><gtr:title>Reciprocal relationship between expression of hypoxia inducible factor 1alpha (HIF-1alpha) and the pro-apoptotic protein bid in ex vivo colorectal cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7c12d93e30291af12726be1096c34fe"><gtr:id>d7c12d93e30291af12726be1096c34fe</gtr:id><gtr:otherNames>Seenath MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>03EA5C2BFA0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2049FC96-973F-4C6C-8833-693DFEDA0967</gtr:id><gtr:title>Radiosensitizers of hypoxic mammalian cells. 1-(Hydroxyaminoalkyl)-substituted nitroimidazoles.</gtr:title><gtr:parentPublicationTitle>Arzneimittel-Forschung</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bd811a5fe1bfd6f608c2b2af9425977"><gtr:id>6bd811a5fe1bfd6f608c2b2af9425977</gtr:id><gtr:otherNames>Ahmed I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1985-01-01</gtr:date><gtr:issn>0004-4172</gtr:issn><gtr:outcomeId>pm_14036_436_4096727</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B987F1F7-8BB3-4376-B345-583FAB7074B6</gtr:id><gtr:title>Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/656ac39f329efa3aa52789c6b18520de"><gtr:id>656ac39f329efa3aa52789c6b18520de</gtr:id><gtr:otherNames>Lallana E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>5aa91f3a78b960.27356194</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BCCA6F6-440C-432D-899A-2E683D761691</gtr:id><gtr:title>Bioreductive drugs: from concept to clinic.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b347b0b5edce22dacb514874aac86cf"><gtr:id>1b347b0b5edce22dacb514874aac86cf</gtr:id><gtr:otherNames>McKeown SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>F1B6F2D7481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FB0EAF0-584D-4220-A13F-9B0AA72C5AF2</gtr:id><gtr:title>The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10467f57da5334e2e48ec4bc351ca634"><gtr:id>10467f57da5334e2e48ec4bc351ca634</gtr:id><gtr:otherNames>Lunt SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>HM5rJvCWpNC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2915C400-3112-41DA-A897-5DF6895D5A26</gtr:id><gtr:title>Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/782c336ca9b82847685504c7a7765613"><gtr:id>782c336ca9b82847685504c7a7765613</gtr:id><gtr:otherNames>Patterson AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1995-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7577460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE837906-349C-40A8-BEDB-E151EB0FA562</gtr:id><gtr:title>The effect of caffeine on the cytotoxicity of misonidazole and some other nitroheterocyclic compounds.</gtr:title><gtr:parentPublicationTitle>Chemico-biological interactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/499fe2593ed6cd8891cf320181ee82a9"><gtr:id>499fe2593ed6cd8891cf320181ee82a9</gtr:id><gtr:otherNames>Horsman MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0009-2797</gtr:issn><gtr:outcomeId>pm_14036_736_7105250</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDF795CC-7069-4BD6-8311-5E9CF16E0516</gtr:id><gtr:title>Thermotolerance in chinese hamster cells under oxic conditions after chronic culture under hypoxia.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5ed41c10c67d923e19464612841d744"><gtr:id>b5ed41c10c67d923e19464612841d744</gtr:id><gtr:otherNames>Rajaratnam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1981-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7236493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>000BAF55-CDA1-4769-9400-3431166EB431</gtr:id><gtr:title>2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ece4fc336f814cb4f7184b3ffa4e9ff"><gtr:id>5ece4fc336f814cb4f7184b3ffa4e9ff</gtr:id><gtr:otherNames>Naylor MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_136_1404237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0735C39B-A3D8-49D1-9991-2482FA3703D2</gtr:id><gtr:title>Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcea06ec65ff0679c17eaf0561024757"><gtr:id>fcea06ec65ff0679c17eaf0561024757</gtr:id><gtr:otherNames>Nolan KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>jTWyz9a1jbT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2DB2545-1827-4341-976D-3D4639CE31B6</gtr:id><gtr:title>Bioreductive drugs for cancer therapy: the search for tumor specificity.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_836_8195012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B95D833C-0B76-4689-B9B7-CE667AFAF89E</gtr:id><gtr:title>Targeting gene expression to hypoxic tumor cells.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56dba8efeb280f62f644d59640315cdb"><gtr:id>56dba8efeb280f62f644d59640315cdb</gtr:id><gtr:otherNames>Dachs GU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>pm_14036_936_9142119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0994371E-7AA9-46DD-A1F0-DE325FBADE0B</gtr:id><gtr:title>The role of cavitation in the interaction of ultrasound with V79 Chinese hamster cells in vitro.</gtr:title><gtr:parentPublicationTitle>The British journal of cancer. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/353cf45e493641a0eccabf01b532ce55"><gtr:id>353cf45e493641a0eccabf01b532ce55</gtr:id><gtr:otherNames>Morton KI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0306-9443</gtr:issn><gtr:outcomeId>pm_14036_636_6950750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B37B930-3669-404C-88A5-1792B793921D</gtr:id><gtr:title>Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c6af3e75e7d345fe089002cb560c56f"><gtr:id>7c6af3e75e7d345fe089002cb560c56f</gtr:id><gtr:otherNames>West CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_16_16029781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5177B8BF-F5DC-47E9-9505-B22D73626550</gtr:id><gtr:title>Protection against misonidazole-induced neuropathy in rats: a biochemical assessment.</gtr:title><gtr:parentPublicationTitle>Toxicology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b061f5c6b8438778a75119b67096a9a3"><gtr:id>b061f5c6b8438778a75119b67096a9a3</gtr:id><gtr:otherNames>Rose GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1983-01-01</gtr:date><gtr:issn>0378-4274</gtr:issn><gtr:outcomeId>pm_14036_636_6414109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>461D42EF-E69E-4181-B207-993A89709E38</gtr:id><gtr:title>Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9e9e99dac0333d4caefbc8afb51ee13"><gtr:id>c9e9e99dac0333d4caefbc8afb51ee13</gtr:id><gtr:otherNames>Reigan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_16_15658853</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5486CA3F-6556-494D-952C-CAC0DFA7829A</gtr:id><gtr:title>Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_136_1544844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEE03ED6-569E-4FBA-B16D-0A83A276627C</gtr:id><gtr:title>High uptake of RSU 1069 and its analogues melanotic melanomas.</gtr:title><gtr:parentPublicationTitle>Cancer chemotherapy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5ca56685283bdb73fae9518c0f514b7"><gtr:id>d5ca56685283bdb73fae9518c0f514b7</gtr:id><gtr:otherNames>Walling JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0344-5704</gtr:issn><gtr:outcomeId>pm_14036_236_2541936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF26078D-8960-43C4-B430-2461DB228EB9</gtr:id><gtr:title>Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b63ef2964be52003b3981c9ddd321c65"><gtr:id>b63ef2964be52003b3981c9ddd321c65</gtr:id><gtr:otherNames>Dunstan MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>Vb6xDnHQAv1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F634BA76-0C19-4C4E-A0B6-C26D42659CD2</gtr:id><gtr:title>Protection of pig epidermis against radiation-induced damage by the infusion of BW12C.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba593b87eb37a70ae4082b1688e3c13c"><gtr:id>ba593b87eb37a70ae4082b1688e3c13c</gtr:id><gtr:otherNames>van den Aardweg GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1991-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>pm_14036_136_1674270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E27416F8-A76D-4688-BE7D-4B40DFEF63DB</gtr:id><gtr:title>Mechanism of action of some bioreducible 2-nitroimidazoles: comparison of in vitro cytotoxicity and ability to induce DNA strand breakage.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a584bbe8397db70008454ebc586e86f"><gtr:id>5a584bbe8397db70008454ebc586e86f</gtr:id><gtr:otherNames>O'Neill P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1987-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_336_3450299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>529194CF-511E-4E10-8C70-1751A6D80729</gtr:id><gtr:title>Pretreatment apoptosis in carcinoma of the cervix correlates with changes in tumour oxygenation during radiotherapy.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/651a157d4c5cb8a7325da84d4467ff4b"><gtr:id>651a157d4c5cb8a7325da84d4467ff4b</gtr:id><gtr:otherNames>Sheridan MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2000-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_16_10735502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFAD22E1-A3A1-4D07-A3A8-36C01BE13C4B</gtr:id><gtr:title>Chemosensitization by monofunctional alkylating agents.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5ca56685283bdb73fae9518c0f514b7"><gtr:id>d5ca56685283bdb73fae9518c0f514b7</gtr:id><gtr:otherNames>Walling JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1986-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_336_3759563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D51E545D-FA9E-416C-AC6A-F4CDF1C7483B</gtr:id><gtr:title>The interaction of misonidazole with radiation, chemotherapeutic agents, or heat: a preliminary report.</gtr:title><gtr:parentPublicationTitle>Cancer clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1980-01-01</gtr:date><gtr:issn>0190-1206</gtr:issn><gtr:outcomeId>pm_14036_736_7192182</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>398427E6-CA96-4A7C-A3A6-B4159D8E5794</gtr:id><gtr:title>Enhancement of the anti-tumor effect of melphalan in experimental mice by some vaso-active agents.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_236_2715059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>524E115F-C781-4AF9-8634-D2A3FB7165DC</gtr:id><gtr:title>Cyclopropamitosenes: novel bioreductive anticancer agents--mechanism of action and enzymic reduction.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c92ff6ddb6acecd77b99c636b7b08a62"><gtr:id>c92ff6ddb6acecd77b99c636b7b08a62</gtr:id><gtr:otherNames>Moody CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0959-4973</gtr:issn><gtr:outcomeId>pm_14036_736_7919462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D46A470-D1A9-41BB-9021-949A14F1C097</gtr:id><gtr:title>Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9ec54f24725aaffd339fc1104277cb"><gtr:id>fb9ec54f24725aaffd339fc1104277cb</gtr:id><gtr:otherNames>Jenkins TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1990-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_236_2391699</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8D59C64-E34E-4FBC-988F-422FB242FA09</gtr:id><gtr:title>Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2fec698a5b28ec20ea31e93994132f5"><gtr:id>b2fec698a5b28ec20ea31e93994132f5</gtr:id><gtr:otherNames>Hutchison GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_14036_16_15623619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>422A2277-1E68-42A3-BCE6-5355DE2E3A0F</gtr:id><gtr:title>Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5869614856aaf76a752f6c9e9a84edfb"><gtr:id>5869614856aaf76a752f6c9e9a84edfb</gtr:id><gtr:otherNames>Green MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>BBEA7F79543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F3DF1C5-6537-4AAC-B13F-767EE268097D</gtr:id><gtr:title>Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe5b324e59d9c2c7947f50b50e49a2a"><gtr:id>7fe5b324e59d9c2c7947f50b50e49a2a</gtr:id><gtr:otherNames>McNally VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_14036_16_14552762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4358AC8-FEAB-411B-B7F8-1A165F33F8C5</gtr:id><gtr:title>Enzymology of tirapazamine metabolism: a review.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/782c336ca9b82847685504c7a7765613"><gtr:id>782c336ca9b82847685504c7a7765613</gtr:id><gtr:otherNames>Patterson AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1998-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_936_9755718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3D043BE-C3D9-4CD4-B4D4-DF3E2D807223</gtr:id><gtr:title>Electron-affinic sensitization VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. 1976.</gtr:title><gtr:parentPublicationTitle>Radiation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0033-7587</gtr:issn><gtr:outcomeId>pm_14036_26_22870968</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FA7240F-A0C9-4D8B-981B-3C87BE24560C</gtr:id><gtr:title>Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b3f94ca7cde4b79ce961997950ca9b9"><gtr:id>8b3f94ca7cde4b79ce961997950ca9b9</gtr:id><gtr:otherNames>Oliver RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>pm_14036_16_14962715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD1A94F7-2552-45CD-9D1B-2B23499E06A8</gtr:id><gtr:title>Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71505d62178dc25e4da5f5bc99be7e81"><gtr:id>71505d62178dc25e4da5f5bc99be7e81</gtr:id><gtr:otherNames>Cole S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1991-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_236_2061115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9FB6287-1229-437B-9119-5FBE50F7CB7B</gtr:id><gtr:title>A comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids.</gtr:title><gtr:parentPublicationTitle>Cancer chemotherapy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c6af3e75e7d345fe089002cb560c56f"><gtr:id>7c6af3e75e7d345fe089002cb560c56f</gtr:id><gtr:otherNames>West CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1987-01-01</gtr:date><gtr:issn>0344-5704</gtr:issn><gtr:outcomeId>pm_14036_236_2822273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F99726CF-7D49-4548-A63E-14783673E55D</gtr:id><gtr:title>Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6658300fa5d316c46fb9cf17c86cd733"><gtr:id>6658300fa5d316c46fb9cf17c86cd733</gtr:id><gtr:otherNames>Houlbrook S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1995-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_836_8519659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>960CA535-9620-4EDE-BFE6-214028462859</gtr:id><gtr:title>Induction of severe tumor hypoxia by modifiers of the oxygen affinity of hemoglobin.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_236_2715067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B3B0D32-3E38-40FC-8860-D5F2567FE236</gtr:id><gtr:title>Mechanisms of hypoxic cell radiosensitization and the development of new sensitizers.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_736_7050037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35CF7CC1-08E2-4719-97E1-8018E98BB670</gtr:id><gtr:title>Pharmacological inhibitors of NAD(P)H quinone oxidoreductase, NQO1: structure/activity relationships and functional activity in tumour cells.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcea06ec65ff0679c17eaf0561024757"><gtr:id>fcea06ec65ff0679c17eaf0561024757</gtr:id><gtr:otherNames>Nolan KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>UEyQhUFDRR8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E55A941D-0BBC-49EC-9DB7-073CD85428A6</gtr:id><gtr:title>Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1991-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>pm_14036_236_2020774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DC07275-A4AA-44CA-A582-C2A5B1F4E962</gtr:id><gtr:title>Investigation of radiosensitivity gene signatures in cancer cell lines.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b7c4a23a0db5531afb26d42590fe854"><gtr:id>5b7c4a23a0db5531afb26d42590fe854</gtr:id><gtr:otherNames>Hall JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5464a552435485.19594024</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96A8E351-CB35-4287-A15F-50FBC3A153FE</gtr:id><gtr:title>Mammalian cell toxicity of nitro compounds : dependence upon reduction potential.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1976-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>pm_14036_9036_985519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC9FAE31-5DE0-44BD-8D3E-28EC99F275CD</gtr:id><gtr:title>Cancer chemotherapy and drug metabolism.</gtr:title><gtr:parentPublicationTitle>Drug metabolism and disposition: the biological fate of chemicals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01a1c452bd6b8ab6d66949118e353ee1"><gtr:id>01a1c452bd6b8ab6d66949118e353ee1</gtr:id><gtr:otherNames>Riddick DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0090-9556</gtr:issn><gtr:outcomeId>pm_14036_16_16049130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19E0ADC4-9ABC-4908-BC2C-F1BD92E7ADAD</gtr:id><gtr:title>Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ef082f96e626cce81f78fe979e8c994"><gtr:id>0ef082f96e626cce81f78fe979e8c994</gtr:id><gtr:otherNames>Kim JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>pm_14036_16_15064018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B204827A-554A-4953-9F8E-0B8CBE376D53</gtr:id><gtr:title>Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: possible mechanisms involved.</gtr:title><gtr:parentPublicationTitle>Toxicology in vitro : an international journal published in association with BIBRA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2191ac704eefc1b10f206f1d77402a7f"><gtr:id>2191ac704eefc1b10f206f1d77402a7f</gtr:id><gtr:otherNames>Martinez VG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0887-2333</gtr:issn><gtr:outcomeId>24F77520115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88BAB444-D478-4C94-9575-660917B672F6</gtr:id><gtr:title>Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a6c4a731a420e8267004fafb98813a2"><gtr:id>8a6c4a731a420e8267004fafb98813a2</gtr:id><gtr:otherNames>Bola BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>5464a49e3ec535.06584190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>707E3306-35E0-4D47-94FB-30729E27E295</gtr:id><gtr:title>A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7aa20dacdff19ef627b94a216a74db67"><gtr:id>7aa20dacdff19ef627b94a216a74db67</gtr:id><gtr:otherNames>Adlard AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>pm_540e140e140a89076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEE4FB91-B379-4034-A6B7-06919D109046</gtr:id><gtr:title>3-Nitro-1,2,4-triazoles as hypoxia-selective agents.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9ec54f24725aaffd339fc1104277cb"><gtr:id>fb9ec54f24725aaffd339fc1104277cb</gtr:id><gtr:otherNames>Jenkins TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_236_2803463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7642261-8C65-4D1C-B54E-F35FE6C467A4</gtr:id><gtr:title>Acetylation mediated by the p300/CBP-associated factor determines cellular energy metabolic pathways in cancer.</gtr:title><gtr:parentPublicationTitle>International journal of oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/010a1f9027ca603cbc5f6201a5567fd8"><gtr:id>010a1f9027ca603cbc5f6201a5567fd8</gtr:id><gtr:otherNames>Rajendran R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1019-6439</gtr:issn><gtr:outcomeId>pm_14036_26_23591450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F89B6EF-B06F-4A79-88F5-6E024A2163F5</gtr:id><gtr:title>S-2-amino-5-azolylpentanoic acids related to L-ornithine as inhibitors of the isoforms of nitric oxide synthase (NOS).</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d73869bf3be083d43defca6b00741b5"><gtr:id>4d73869bf3be083d43defca6b00741b5</gtr:id><gtr:otherNames>Ulhaq S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1998-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>pm_14036_936_9881104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2B5A4CB-2987-42F0-910F-0CCE500B5336</gtr:id><gtr:title>Combination studies with misonidazole and a cis-platinum complex: cytotoxicity and radiosensitization in vitro.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1980-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7190019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D716E4C6-220F-4BC4-91F2-689C70A29D93</gtr:id><gtr:title>Ultrasonic irradiation of mammalian cells in vitro at hyperthermic temperatures.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e29d3bb3ead33d70dd636926b661d9df"><gtr:id>e29d3bb3ead33d70dd636926b661d9df</gtr:id><gtr:otherNames>ter Haar G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1980-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>pm_14036_736_7437689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09FD37A9-7FEB-4052-8CAC-C8100B9F7B1C</gtr:id><gtr:title>Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1567bd194f9ae2f653b6c5c6fe08850"><gtr:id>b1567bd194f9ae2f653b6c5c6fe08850</gtr:id><gtr:otherNames>Wood PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_14036_736_7987843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B421413B-BF01-4139-8CE6-D3C36423004F</gtr:id><gtr:title>Combining bioreductive drugs and radiation for the treatment of solid tumors.</gtr:title><gtr:parentPublicationTitle>Seminars in radiation oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>1053-4296</gtr:issn><gtr:outcomeId>pm_14036_16_12520463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56D633ED-4D9C-4F02-AAB5-6BECE9A61AF2</gtr:id><gtr:title>Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5869614856aaf76a752f6c9e9a84edfb"><gtr:id>5869614856aaf76a752f6c9e9a84edfb</gtr:id><gtr:otherNames>Green MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_16_15685241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FE32191-3DBC-41F9-A0A6-13B503E32902</gtr:id><gtr:title>Aziridinyl nitropyrroles and nitropyrazoles as hypoxia-selective cytotoxins and radiosensitizers.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ece4fc336f814cb4f7184b3ffa4e9ff"><gtr:id>5ece4fc336f814cb4f7184b3ffa4e9ff</gtr:id><gtr:otherNames>Naylor MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1991-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_136_1872946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB3C4528-4588-4124-A791-A42BDB956F4D</gtr:id><gtr:title>Manipulation and exploitation of the tumour environment for therapeutic benefit.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>pm_14036_736_7905915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F163AE9-02B4-4E86-AB68-BBE1FAD46676</gtr:id><gtr:title>Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1ed274ef4a8f43d1a80f518878b0f06"><gtr:id>a1ed274ef4a8f43d1a80f518878b0f06</gtr:id><gtr:otherNames>Cowen RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>pm_14036_16_14555709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06384F82-FC28-4E78-B9B9-587377C9EECF</gtr:id><gtr:title>Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36293c3b26aa08082e1a512c7242cc6d"><gtr:id>36293c3b26aa08082e1a512c7242cc6d</gtr:id><gtr:otherNames>Chadderton N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_16_15850924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B6B26AC-1AF7-4AA4-A3DC-C12E56C0BB23</gtr:id><gtr:title>Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c897c09b26a809d2af5474f1ab98138"><gtr:id>5c897c09b26a809d2af5474f1ab98138</gtr:id><gtr:otherNames>Yan C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>872F1A92F77</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F80D2457-5E69-46A6-9965-E1D0013BABF0</gtr:id><gtr:title>Hypoxia in tumors: molecular targets for anti-cancer therapeutics.</gtr:title><gtr:parentPublicationTitle>Advances in enzyme regulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3933f2c467c3c3aa83c6cc0807029139"><gtr:id>3933f2c467c3c3aa83c6cc0807029139</gtr:id><gtr:otherNames>Williams KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0065-2571</gtr:issn><gtr:outcomeId>pm_14036_16_15581485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E72CFA7-93D5-48E3-B05F-460403F0B09B</gtr:id><gtr:title>Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bae66f1ffefc35438ffca7121f8ed2f8"><gtr:id>bae66f1ffefc35438ffca7121f8ed2f8</gtr:id><gtr:otherNames>Griffiths L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_936_9310231</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91EB8BDF-4E60-41AF-9D8E-4286CE0000AF</gtr:id><gtr:title>Use of metronidazole and other nitroimidazole drugs in cancer therapy.</gtr:title><gtr:parentPublicationTitle>Cancer treatment reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1978-01-01</gtr:date><gtr:issn>0361-5960</gtr:issn><gtr:outcomeId>pm_14036_6036_688288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97803908-CD30-4005-8703-0C434090E06C</gtr:id><gtr:title>HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72e0c63aa262255ca1b5fdb6a66f846a"><gtr:id>72e0c63aa262255ca1b5fdb6a66f846a</gtr:id><gtr:otherNames>Maxwell PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>CFB85B8794C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F24F8FB1-6237-4964-80CF-305289BB135F</gtr:id><gtr:title>Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model.</gtr:title><gtr:parentPublicationTitle>Journal of biomolecular techniques : JBT</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f466dc8e256d603f888c16a293004e3"><gtr:id>2f466dc8e256d603f888c16a293004e3</gtr:id><gtr:otherNames>Cawthorne C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1524-0215</gtr:issn><gtr:outcomeId>23FCE185AC9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>081EFB4B-64DA-4721-8623-FB050AD0B5D1</gtr:id><gtr:title>Magnetic resonance spectroscopy studies on experimental murine and human tumors: comparison of changes in phosphorus metabolism with induced changes in vascular volume.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_136_1735680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A69191B-8E0D-4502-A0B0-855B58215162</gtr:id><gtr:title>A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3933f2c467c3c3aa83c6cc0807029139"><gtr:id>3933f2c467c3c3aa83c6cc0807029139</gtr:id><gtr:otherNames>Williams KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_14036_16_11803471</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F801DDA3-AC28-400B-9AD6-1BAC910C7C69</gtr:id><gtr:title>Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f8449a0b527399c2b5585cbdb8b68f"><gtr:id>e0f8449a0b527399c2b5585cbdb8b68f</gtr:id><gtr:otherNames>Barham HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_14036_836_8602879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69BF6EE1-5D86-4BF2-BA49-AFB56D202D99</gtr:id><gtr:title>Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/640cf962fed725ff6ea3e649aeadad8a"><gtr:id>640cf962fed725ff6ea3e649aeadad8a</gtr:id><gtr:otherNames>Patterson LH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2000-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_16_10864207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A563709C-D4EF-4A2A-9208-7C28193F4F6C</gtr:id><gtr:title>Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overview.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1986-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_14036_236_2934067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EECEDDC-FBA8-4A9A-9D4E-4A82A2FB0AE4</gtr:id><gtr:title>Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb6d833e61be5c4ba09683407b39387b"><gtr:id>bb6d833e61be5c4ba09683407b39387b</gtr:id><gtr:otherNames>Scott KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>LNXvAqPuumA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06CE2CE1-54D0-4ABF-98C6-6E2C347F0C9C</gtr:id><gtr:title>Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71505d62178dc25e4da5f5bc99be7e81"><gtr:id>71505d62178dc25e4da5f5bc99be7e81</gtr:id><gtr:otherNames>Cole S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>pm_14036_236_2573651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B928DCBD-8856-40A6-A2CC-25B7A5456EA9</gtr:id><gtr:title>Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1984-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_636_6547051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F73ECF4E-5B58-4D18-8C96-75F12A2F22D5</gtr:id><gtr:title>The radiation response of V79 and human tumour multicellular spheroids--cell survival and growth delay studies.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c6af3e75e7d345fe089002cb560c56f"><gtr:id>7c6af3e75e7d345fe089002cb560c56f</gtr:id><gtr:otherNames>West CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1984-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_636_6087864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>867FDFC2-94C6-48ED-8444-65D0B71490F9</gtr:id><gtr:title>The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1a87ff2bff75427786c240df3b36c7f"><gtr:id>a1a87ff2bff75427786c240df3b36c7f</gtr:id><gtr:otherNames>Robertson N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_14036_136_1510692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>068A3EA1-D7B3-4F10-AB58-2C2B722E7FB0</gtr:id><gtr:title>Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fe9d6f80cc66cd68eba859a99c410ed"><gtr:id>6fe9d6f80cc66cd68eba859a99c410ed</gtr:id><gtr:otherNames>Edwards HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1991-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>pm_14036_136_1671692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A211692-E990-4CD2-BF79-21A4044B4C05</gtr:id><gtr:title>Non-symmetrical furan-amidines as novel leads for the treatment of cancer and malaria.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/285f29191565e20edeee2eb87c80c868"><gtr:id>285f29191565e20edeee2eb87c80c868</gtr:id><gtr:otherNames>Alnabulsi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn><gtr:outcomeId>56e00db2dab043.21895616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>063E4B17-F529-47AC-A7BA-94D175B8713C</gtr:id><gtr:title>Radiotherapy research priorities for the UK.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e96a47f840e64fa213f5d842daf1e753"><gtr:id>e96a47f840e64fa213f5d842daf1e753</gtr:id><gtr:otherNames>Maughan TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>Hr4yJmdNS9i</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74DB1EDF-D96E-41C3-ADE1-F2AADD33002B</gtr:id><gtr:title>Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5761caa6a3ab1eecf3e9084b41e5e26f"><gtr:id>5761caa6a3ab1eecf3e9084b41e5e26f</gtr:id><gtr:otherNames>Bremner JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_836_8195028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9703825-421B-4D56-8D5A-3B7A4490C5C8</gtr:id><gtr:title>Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2df091b97894a1b7477c6af3eb03fa5e"><gtr:id>2df091b97894a1b7477c6af3eb03fa5e</gtr:id><gtr:otherNames>Hoban PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1990-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_14036_236_2114946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>923ACBAD-121A-43D7-AE04-72CEAB2EDC11</gtr:id><gtr:title>A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed4cafc36c7856c0695f78152380b4fb"><gtr:id>ed4cafc36c7856c0695f78152380b4fb</gtr:id><gtr:otherNames>Braddock PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7514028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>869B5775-28F7-4659-8768-251072D61E94</gtr:id><gtr:title>Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9e9e99dac0333d4caefbc8afb51ee13"><gtr:id>c9e9e99dac0333d4caefbc8afb51ee13</gtr:id><gtr:otherNames>Reigan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_14036_16_15454205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09218AD9-7276-4AE5-88EF-17E602D3BDDA</gtr:id><gtr:title>In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-?B signaling.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcea06ec65ff0679c17eaf0561024757"><gtr:id>fcea06ec65ff0679c17eaf0561024757</gtr:id><gtr:otherNames>Nolan KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>emx7D2wTgQv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>422E4F9E-829A-4F80-AE9A-B2B953FDE4BB</gtr:id><gtr:title>Bioreductive drugs into the next millennium.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1998-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_936_9755716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A76E5EED-5BF6-4C94-B4F7-5CD10C02A8E6</gtr:id><gtr:title>The decay of potentially lethal oxygen-dependent damage in fully hydrated Bacillus megaterium spores exposed to pulsed electron irradiation.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1977-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_4036_411762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53D3D426-D9B4-439B-BF3E-D26DF91D1CB5</gtr:id><gtr:title>Chemosensitization in vitro: potentiation of melphalan toxicity by misonidazole, metronidazole and nitrofurazone.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189e6bc991e4a601e3505b421420837d"><gtr:id>189e6bc991e4a601e3505b421420837d</gtr:id><gtr:otherNames>Smith E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_736_7107383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F54F504-9372-4A26-A7D6-D51BB7AF81EF</gtr:id><gtr:title>Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicity.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ece4fc336f814cb4f7184b3ffa4e9ff"><gtr:id>5ece4fc336f814cb4f7184b3ffa4e9ff</gtr:id><gtr:otherNames>Naylor MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_836_8195029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>035BB4A0-7B09-4F90-A434-1A12A3BC4A53</gtr:id><gtr:title>iNOS as a therapeutic target for treatment of human tumors.</gtr:title><gtr:parentPublicationTitle>Nitric oxide : biology and chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/869483761c0b93d9a04d66832cb0c507"><gtr:id>869483761c0b93d9a04d66832cb0c507</gtr:id><gtr:otherNames>Fitzpatrick B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1089-8603</gtr:issn><gtr:outcomeId>39B7C2A2290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>091DCECF-E06D-4F4D-AD12-C68AC7821521</gtr:id><gtr:title>Bioreductive and gene therapy approaches to hypoxic diseases.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea87cc2fa9fe5edc388a4f4b5afb23ac"><gtr:id>ea87cc2fa9fe5edc388a4f4b5afb23ac</gtr:id><gtr:otherNames>Jaffar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2001-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>pm_14036_16_11731027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87307436-6028-403E-B3CF-849963247441</gtr:id><gtr:title>Quinone bioreductive prodrugs as delivery agents.</gtr:title><gtr:parentPublicationTitle>Current drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea87cc2fa9fe5edc388a4f4b5afb23ac"><gtr:id>ea87cc2fa9fe5edc388a4f4b5afb23ac</gtr:id><gtr:otherNames>Jaffar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1567-2018</gtr:issn><gtr:outcomeId>pm_14036_16_16305396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1173D1CC-BEB8-46BB-81A4-B11C9BD79136</gtr:id><gtr:title>Preincubation with electron affinic radiosensitizers followed by hyperthermia or X rays.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5ed41c10c67d923e19464612841d744"><gtr:id>b5ed41c10c67d923e19464612841d744</gtr:id><gtr:otherNames>Rajaratnam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_736_7107412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70E896A4-3CA3-4FC3-A4DB-FB30DD5BC70B</gtr:id><gtr:title>Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cea16f69b2a038a830c07fa6159167b"><gtr:id>3cea16f69b2a038a830c07fa6159167b</gtr:id><gtr:otherNames>Loncaster JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2001-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_14036_16_11522632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8914F60C-66B8-46AA-8DBA-DB0956482CA5</gtr:id><gtr:title>Relationship between the melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazole.</gtr:title><gtr:parentPublicationTitle>Cancer chemotherapy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6d738d6f02ff2e15b17bd98a6474b04"><gtr:id>b6d738d6f02ff2e15b17bd98a6474b04</gtr:id><gtr:otherNames>el Gamoussi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>0344-5704</gtr:issn><gtr:outcomeId>pm_14036_836_8422690</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79DB07E3-3012-41A1-8491-110C0B099182</gtr:id><gtr:title>Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d60fa6bf7fbb20b15a40b33e96d6a71f"><gtr:id>d60fa6bf7fbb20b15a40b33e96d6a71f</gtr:id><gtr:otherNames>Kirk J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_14036_736_7914404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE77DADC-97F8-4C65-856F-58DA22379249</gtr:id><gtr:title>S-2-amino-5-(2-nitroimidazol-1-yl)pentanoic acid: a model for potential bioreductively activated prodrugs for inhibitors of nitric oxide synthase (NOS) activity.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d73869bf3be083d43defca6b00741b5"><gtr:id>4d73869bf3be083d43defca6b00741b5</gtr:id><gtr:otherNames>Ulhaq S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_936_9051114</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>646CAF13-3AE5-40BA-8F9D-8B4E5E405909</gtr:id><gtr:title>Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropamitosenes and related indolequinones.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd3356fc689896474fa0c2a9acc8a24c"><gtr:id>dd3356fc689896474fa0c2a9acc8a24c</gtr:id><gtr:otherNames>Cotterill AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_736_7966141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5D9E1D6-63DF-437D-A933-BB07AA0C8431</gtr:id><gtr:title>Synthesis and cytotoxic activity of N-(2-chloroethyl)-N-nitroureas and N-(2-chloroethyl)-N-nitrocarbamates.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c78d7763e5d0d9e650435d1eeb3c7c64"><gtr:id>c78d7763e5d0d9e650435d1eeb3c7c64</gtr:id><gtr:otherNames>Boty?nszki J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0959-4973</gtr:issn><gtr:outcomeId>pm_14036_16_10630358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85113DB7-DD21-40DA-AF4C-5B576B140B56</gtr:id><gtr:title>Evaluation of novel radiation sensitizers in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_736_7107361</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F21863F-CD3D-42C9-8FD5-78E8E02DCD0E</gtr:id><gtr:title>Gene therapy approaches to enhance bioreductive drug treatment.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1ed274ef4a8f43d1a80f518878b0f06"><gtr:id>a1ed274ef4a8f43d1a80f518878b0f06</gtr:id><gtr:otherNames>Cowen RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>D781D2A7155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>434505F2-7EBA-42C5-A9CF-66D6EE1D6AFF</gtr:id><gtr:title>Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3933f2c467c3c3aa83c6cc0807029139"><gtr:id>3933f2c467c3c3aa83c6cc0807029139</gtr:id><gtr:otherNames>Williams KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>pm_14036_16_15878106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0222376-938B-4A62-835C-BE75F3B95387</gtr:id><gtr:title>A synthetic approach to novel carvotacetone and antheminone analogues with anti-tumour activity.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2160808052d392c356e75a042b504ae"><gtr:id>d2160808052d392c356e75a042b504ae</gtr:id><gtr:otherNames>Christou S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_14036_26_23937978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FED6E30-8D56-46AF-9E0D-B5C501AA340E</gtr:id><gtr:title>The bioreductive agent RH1 and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ef082f96e626cce81f78fe979e8c994"><gtr:id>0ef082f96e626cce81f78fe979e8c994</gtr:id><gtr:otherNames>Kim JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_16_14751506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B166F0E-2ED1-467A-B89C-83E1C3B14CDD</gtr:id><gtr:title>Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dabf7c233701296c60b9d52f3d3a97e5"><gtr:id>dabf7c233701296c60b9d52f3d3a97e5</gtr:id><gtr:otherNames>Roberts DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>DD2FAE464B7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F21AF2A5-0C67-40B6-AE51-2D210FD2B424</gtr:id><gtr:title>Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth.</gtr:title><gtr:parentPublicationTitle>Endocrine-related cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14cb853494fb013ce18bc03594bf0ca"><gtr:id>c14cb853494fb013ce18bc03594bf0ca</gtr:id><gtr:otherNames>Sommer P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1351-0088</gtr:issn><gtr:outcomeId>SY8dbSXTuhi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>218E2601-5812-479B-8129-82C4E0FEA167</gtr:id><gtr:title>Combination of photodynamic therapy (PDT) and melphalan in experimental tumors.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea248a764af5491580fc25ce50dd511d"><gtr:id>ea248a764af5491580fc25ce50dd511d</gtr:id><gtr:otherNames>Sansom JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_836_8005800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22630239-1194-4B22-B93A-C855943EC1C9</gtr:id><gtr:title>Concepts and developments in radiosensitization of mammalian cells.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_136_1735691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CACBFAF1-6A96-4FD4-8F59-FB73F97E67A7</gtr:id><gtr:title>Guidelines for the welfare and use of animals in cancer research.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acfc3fc3032aa1ca2c1d9e812cb8be4c"><gtr:id>acfc3fc3032aa1ca2c1d9e812cb8be4c</gtr:id><gtr:otherNames>Workman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>doeLAYELvbL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88103537-3318-4BC7-B438-7A85DA2AEAAC</gtr:id><gtr:title>Structure-activity relationships in the development of hypoxic cell radiosensitizers. III. Effects of basic substituents in nitroimidazole sidechains.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1980-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_636_6970731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B3ECC63-A3DF-443E-A92D-F38AC22365E0</gtr:id><gtr:title>A metabolite of the 2-nitroimidazole misonidazole with radiosensitizing properties.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd9504fce3eff7aa3a4f8fe0266abdad"><gtr:id>fd9504fce3eff7aa3a4f8fe0266abdad</gtr:id><gtr:otherNames>Flockhart IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1978-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_3036_309446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB98BDB9-99AC-49DD-A64D-F37F4C995ADA</gtr:id><gtr:title>The response of spontaneous and transplantable murine tumors to vasoactive agents measured by 31P magnetic resonance spectroscopy.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1567bd194f9ae2f653b6c5c6fe08850"><gtr:id>b1567bd194f9ae2f653b6c5c6fe08850</gtr:id><gtr:otherNames>Wood PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_136_1735681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3776F5CD-DA36-4AC1-A4A4-93C120B0B2D3</gtr:id><gtr:title>The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/126fc3c1f8ddcb84da5f7324befc7942"><gtr:id>126fc3c1f8ddcb84da5f7324befc7942</gtr:id><gtr:otherNames>Saunders MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2000-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_14036_16_10692564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F62B9BCF-91E7-4EE0-9712-D3F9A3FFBAE6</gtr:id><gtr:title>Targeting gene therapy to cancer: a review.</gtr:title><gtr:parentPublicationTitle>Oncology research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56dba8efeb280f62f644d59640315cdb"><gtr:id>56dba8efeb280f62f644d59640315cdb</gtr:id><gtr:otherNames>Dachs GU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0965-0407</gtr:issn><gtr:outcomeId>pm_14036_936_9406237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0676B9E9-D057-4999-AE9E-00A6CF806BD8</gtr:id><gtr:title>Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f080fb13c1eb5b661cdb0c95f241413"><gtr:id>7f080fb13c1eb5b661cdb0c95f241413</gtr:id><gtr:otherNames>Garner AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_14036_16_10213502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB351892-7073-488D-B1F1-6CD9F3A53E7E</gtr:id><gtr:title>No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1686fa022386186140bcbbb69b43fcc"><gtr:id>b1686fa022386186140bcbbb69b43fcc</gtr:id><gtr:otherNames>Kabuubi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>483539474D8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98E2BC2B-E27C-401C-8657-09A12EAE5E68</gtr:id><gtr:title>Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase.</gtr:title><gtr:parentPublicationTitle>Oncology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f0d971c09a08721e5f9c5d070e30f01"><gtr:id>1f0d971c09a08721e5f9c5d070e30f01</gtr:id><gtr:otherNames>Mehibel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1021-335X</gtr:issn><gtr:outcomeId>56e00db30df4f2.03397625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FA4F215-0574-4CDD-8C9D-15BFD597BFC0</gtr:id><gtr:title>Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f0d971c09a08721e5f9c5d070e30f01"><gtr:id>1f0d971c09a08721e5f9c5d070e30f01</gtr:id><gtr:otherNames>Mehibel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>719A40CD84A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE9DB989-1019-4C0B-ADDD-7EA4C4FEE8CB</gtr:id><gtr:title>The toxicity of the radiosensitizer misonidazole towards hypoxic cells in vitro: a model for mouse and man.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1978-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>pm_14036_6036_698523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79CB13A4-B85C-4A0F-82FB-DB628CA685DD</gtr:id><gtr:title>3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea87cc2fa9fe5edc388a4f4b5afb23ac"><gtr:id>ea87cc2fa9fe5edc388a4f4b5afb23ac</gtr:id><gtr:otherNames>Jaffar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_14036_16_14505799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA7C0E07-A980-4341-A98E-4597B8821EF2</gtr:id><gtr:title>Design, synthesis and enzymatic evaluation of 6-bridged imidazolyluracil derivatives as inhibitors of human thymidine phosphorylase.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe5b324e59d9c2c7947f50b50e49a2a"><gtr:id>7fe5b324e59d9c2c7947f50b50e49a2a</gtr:id><gtr:otherNames>McNally VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn><gtr:outcomeId>79FD9CF762E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F352040-E481-4B1D-86FE-C5D9C3058F71</gtr:id><gtr:title>Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ece4fc336f814cb4f7184b3ffa4e9ff"><gtr:id>5ece4fc336f814cb4f7184b3ffa4e9ff</gtr:id><gtr:otherNames>Naylor MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1990-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_236_2391690</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EDF4CDC-2B58-422B-86EB-2010A9CB6172</gtr:id><gtr:title>Split dose cytotoxic experiments with misonidazole.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1978-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_6036_687510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF935A51-D8DA-49FC-AC63-2C4A77A06BE1</gtr:id><gtr:title>Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22b06ec69d0137bb4a231178d116e464"><gtr:id>22b06ec69d0137bb4a231178d116e464</gtr:id><gtr:otherNames>Cole C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_16_12519058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70837B53-0264-42EE-9E0F-59E8FEE0BD45</gtr:id><gtr:title>Chirality of a 1,10-bisacetoxymitosene compound. Impact on reductive activation, DNA interstrand cross-linking and antitumour activity.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7668af046d1701c27b0286a63a899f9d"><gtr:id>7668af046d1701c27b0286a63a899f9d</gtr:id><gtr:otherNames>Maliepaard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_836_8765532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EEC353E-8515-4E12-986D-ED668A25AD7A</gtr:id><gtr:title>Insoluble derivatives of polynucleotide-phosphorylase.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78f16a250666d83fdc2fa5c8c58c8913"><gtr:id>78f16a250666d83fdc2fa5c8c58c8913</gtr:id><gtr:otherNames>Smith JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1973-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>pm_14036_16_11947104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E37CAFE-A2DF-4775-A2EC-E022F35B410B</gtr:id><gtr:title>Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97e20995adc78d1b4f771eda095edb92"><gtr:id>97e20995adc78d1b4f771eda095edb92</gtr:id><gtr:otherNames>Butler SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_936_9275019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAF707FB-8CCF-4B47-B99E-DDBB36F61A02</gtr:id><gtr:title>Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines.</gtr:title><gtr:parentPublicationTitle>Anticancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6658300fa5d316c46fb9cf17c86cd733"><gtr:id>6658300fa5d316c46fb9cf17c86cd733</gtr:id><gtr:otherNames>Houlbrook S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0250-7005</gtr:issn><gtr:outcomeId>pm_14036_836_8712677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FFE0646-598A-4B5C-A853-6CF03E619813</gtr:id><gtr:title>The development of some nitroimidazoles as hypoxic cell sensitizers.</gtr:title><gtr:parentPublicationTitle>Cancer clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1980-01-01</gtr:date><gtr:issn>0190-1206</gtr:issn><gtr:outcomeId>pm_14036_736_7389035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>279BAB48-3EC8-45C8-AC44-3D876C4A7EFE</gtr:id><gtr:title>Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35642fe4934edf33ada9af77afaeff75"><gtr:id>35642fe4934edf33ada9af77afaeff75</gtr:id><gtr:otherNames>Fielden EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_136_1544842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C0C132C-C52A-426D-8571-ADCFA71BF24F</gtr:id><gtr:title>Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1567bd194f9ae2f653b6c5c6fe08850"><gtr:id>b1567bd194f9ae2f653b6c5c6fe08850</gtr:id><gtr:otherNames>Wood PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_736_7516319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E40728F2-5967-40F9-96BD-1EA4041694FA</gtr:id><gtr:title>ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3933f2c467c3c3aa83c6cc0807029139"><gtr:id>3933f2c467c3c3aa83c6cc0807029139</gtr:id><gtr:otherNames>Williams KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_16_11953865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD2D78B0-E89D-4DD2-A4F7-F1AA96B6F4BE</gtr:id><gtr:title>Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68cb105cc7153345bde6f30da0f663f1"><gtr:id>68cb105cc7153345bde6f30da0f663f1</gtr:id><gtr:otherNames>Searle EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5464a510bf2a12.28756326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>107BFD0B-914F-46C0-AA77-56B2CD332681</gtr:id><gtr:title>Thiol reactive nitroimidazoles: radiosensitization studies in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1984-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_636_6335498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9C12CD2-6CE6-4897-BCF8-CC5ADF8EC6C0</gtr:id><gtr:title>Structure-activity relationships in the development of hypoxic cell radiosensitizers. II. Cytotoxicity and therapeutic ratio.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1979-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_3036_312784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B847364F-7A4D-4304-A56D-14C8D5A76AB5</gtr:id><gtr:title>In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcea06ec65ff0679c17eaf0561024757"><gtr:id>fcea06ec65ff0679c17eaf0561024757</gtr:id><gtr:otherNames>Nolan KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>oT2C1tkENcC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D966C771-B866-42BB-A87F-56544C095F5E</gtr:id><gtr:title>Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d431cedaa861432f10f63dcdd4b465a"><gtr:id>9d431cedaa861432f10f63dcdd4b465a</gtr:id><gtr:otherNames>Calabrese CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>pm_14036_16_14709739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90355EA8-9D37-4522-87AB-14CCD47D3E73</gtr:id><gtr:title>Synthesis and cytotoxic activity of indolyl thiazoles.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c92ff6ddb6acecd77b99c636b7b08a62"><gtr:id>c92ff6ddb6acecd77b99c636b7b08a62</gtr:id><gtr:otherNames>Moody CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0959-4973</gtr:issn><gtr:outcomeId>pm_14036_936_9215613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33905379-BFE1-431B-8ED2-D05852277966</gtr:id><gtr:title>The experimental development of bioreductive drugs and their role in cancer therapy.</gtr:title><gtr:parentPublicationTitle>Cancer metastasis reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acfc3fc3032aa1ca2c1d9e812cb8be4c"><gtr:id>acfc3fc3032aa1ca2c1d9e812cb8be4c</gtr:id><gtr:otherNames>Workman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>0167-7659</gtr:issn><gtr:outcomeId>pm_14036_836_8375022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FBADDE5-548D-4C9A-9CDF-151418891085</gtr:id><gtr:title>The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ef082f96e626cce81f78fe979e8c994"><gtr:id>0ef082f96e626cce81f78fe979e8c994</gtr:id><gtr:otherNames>Kim JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0959-4973</gtr:issn><gtr:outcomeId>pm_14036_16_15090746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11D91912-FDB9-4015-A45B-F87EA32EF041</gtr:id><gtr:title>Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9e9e99dac0333d4caefbc8afb51ee13"><gtr:id>c9e9e99dac0333d4caefbc8afb51ee13</gtr:id><gtr:otherNames>Reigan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn><gtr:outcomeId>21B9AF11085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>315B4879-6B33-416B-AEF6-4525C69CB186</gtr:id><gtr:title>Radiosensitizing activity of 1-alkyl-3-nitropyrrolo-(2,3-b)-pyridine derivative.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e52e4e7811a88ba30a78381a0bde910"><gtr:id>5e52e4e7811a88ba30a78381a0bde910</gtr:id><gtr:otherNames>Jin YZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_236_2921139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58C03B5B-8CEF-42B6-898E-00CCFF3B67A3</gtr:id><gtr:title>RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1984-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_636_6548211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B7C9BCB-3EC1-47C8-9BC3-A2DC78C0007D</gtr:id><gtr:title>Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f8449a0b527399c2b5585cbdb8b68f"><gtr:id>e0f8449a0b527399c2b5585cbdb8b68f</gtr:id><gtr:otherNames>Barham HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_836_8883403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A22A333E-2A64-46C1-86C1-D347336A7E86</gtr:id><gtr:title>Arene cis-dihydrodiols: useful precursors for the preparation of analogues of the anti-tumour agent, 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC).</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b0f03b7be362959993efa2939ad5e3d"><gtr:id>1b0f03b7be362959993efa2939ad5e3d</gtr:id><gtr:otherNames>Arthurs CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>056319C4671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93024014-1687-4C34-A0B2-A9C36127277B</gtr:id><gtr:title>High efficiency of ferricenium salts as radiosensitizers of V79 cells in vitro and the KHT tumor in vivo.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b5e03d65e4e6e4b450f830516db9d0a"><gtr:id>5b5e03d65e4e6e4b450f830516db9d0a</gtr:id><gtr:otherNames>Joy AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_236_2703386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA7307EB-1B3B-4720-8E2B-8D1652744393</gtr:id><gtr:title>Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts.</gtr:title><gtr:parentPublicationTitle>International journal of oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/969ca5ae814248b666d6e3479f9a68dc"><gtr:id>969ca5ae814248b666d6e3479f9a68dc</gtr:id><gtr:otherNames>Airley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1019-6439</gtr:issn><gtr:outcomeId>pm_14036_16_15870859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCBA3023-C774-42B1-B8DC-4DEC3570652A</gtr:id><gtr:title>Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin--implications for therapy.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1986-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_336_3759551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B741D28A-98CB-4BE0-8F97-0950F540CB95</gtr:id><gtr:title>A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour.</gtr:title><gtr:parentPublicationTitle>Acta oncologica (Stockholm, Sweden)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1567bd194f9ae2f653b6c5c6fe08850"><gtr:id>b1567bd194f9ae2f653b6c5c6fe08850</gtr:id><gtr:otherNames>Wood PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0284-186X</gtr:issn><gtr:outcomeId>pm_14036_936_9023383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7263A30E-F063-4159-A13C-7EFA961A7667</gtr:id><gtr:title>Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49a45bc2b3cb7e3f4064a9dce2caec9a"><gtr:id>49a45bc2b3cb7e3f4064a9dce2caec9a</gtr:id><gtr:otherNames>Silk JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>pm_14036_16_15599405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>880FD2E0-1492-47E0-A6FE-E7335764B7FF</gtr:id><gtr:title>Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f42fabb427c442795033b7b2414086db"><gtr:id>f42fabb427c442795033b7b2414086db</gtr:id><gtr:otherNames>Janssen HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>pm_14036_16_15036858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDE97F31-AE53-41B0-94BF-9A2A31D1A942</gtr:id><gtr:title>Synthesis of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas and evaluation as modulators of the isoforms of nitric oxide synthase.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6b0ee4344ed2d2a4a13b560d8687f16"><gtr:id>a6b0ee4344ed2d2a4a13b560d8687f16</gtr:id><gtr:otherNames>Goodyer CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>pm_14036_16_12951150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07F01A0E-C601-4679-A61B-77F0B4BD4533</gtr:id><gtr:title>Radiosensitizing and cytotoxic effects of nitroimidazoles in CHO cells expressing elevated levels of glutathione-S-transferase.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_236_2523884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>727EA1A8-740D-4569-834B-1BD712AB6986</gtr:id><gtr:title>Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/218498b151dfe74f32ef2bdc8c90195f"><gtr:id>218498b151dfe74f32ef2bdc8c90195f</gtr:id><gtr:otherNames>Walling J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1988-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_336_3258298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E054E679-660E-496C-B67F-00F9B3725927</gtr:id><gtr:title>In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5761caa6a3ab1eecf3e9084b41e5e26f"><gtr:id>5761caa6a3ab1eecf3e9084b41e5e26f</gtr:id><gtr:otherNames>Bremner JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1991-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_136_1931606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A59A7190-62A7-4FBF-A863-4FCA73EBC6AA</gtr:id><gtr:title>The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bae66f1ffefc35438ffca7121f8ed2f8"><gtr:id>bae66f1ffefc35438ffca7121f8ed2f8</gtr:id><gtr:otherNames>Griffiths L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_14036_936_9044826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCD703AA-B100-4A9B-AA97-2F643197FC0E</gtr:id><gtr:title>Time-dependence and preliminary SAR studies in inhibition of nitric oxide synthase isoforms by homologues of thiocitrulline.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6b0ee4344ed2d2a4a13b560d8687f16"><gtr:id>a6b0ee4344ed2d2a4a13b560d8687f16</gtr:id><gtr:otherNames>Goodyer CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_14036_16_14552756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9040D1D3-99E3-449C-92BB-9658153E329E</gtr:id><gtr:title>Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea8cb99b7f48bb89cf9f3645959d4cdf"><gtr:id>ea8cb99b7f48bb89cf9f3645959d4cdf</gtr:id><gtr:otherNames>Griffiths JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_14036_16_11830521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43E781CC-1799-4633-A6D6-EB87701640CB</gtr:id><gtr:title>Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bb4dd9b75cf9cd63bfa8d9acfff7a52"><gtr:id>9bb4dd9b75cf9cd63bfa8d9acfff7a52</gtr:id><gtr:otherNames>Senra JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>NcsMcoGQPTX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8711D1FD-381F-49F6-A1E6-9840058F97FE</gtr:id><gtr:title>Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.</gtr:title><gtr:parentPublicationTitle>Radiation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71505d62178dc25e4da5f5bc99be7e81"><gtr:id>71505d62178dc25e4da5f5bc99be7e81</gtr:id><gtr:otherNames>Cole S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1990-01-01</gtr:date><gtr:issn>0033-7587</gtr:issn><gtr:outcomeId>pm_14036_236_2236508</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7506622-3F6A-498E-B02E-E12EBADD8E17</gtr:id><gtr:title>A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc30db47a24cfb0943f50483f5c514b4"><gtr:id>fc30db47a24cfb0943f50483f5c514b4</gtr:id><gtr:otherNames>Parker LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_16_15509167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94E3B317-FB0C-4FD1-91A8-1B9F8AA62FA5</gtr:id><gtr:title>Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07cc9d1ad80b244dd89bf00d19bdbed7"><gtr:id>07cc9d1ad80b244dd89bf00d19bdbed7</gtr:id><gtr:otherNames>Brown LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>A7BFC717A2D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E4B1412-8955-4A46-9FDD-B02D94246C8A</gtr:id><gtr:title>Clinical development of new drug-radiotherapy combinations.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca7a5462f5e4503ad848595f417ef08f"><gtr:id>ca7a5462f5e4503ad848595f417ef08f</gtr:id><gtr:otherNames>Sharma RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>58c82a418c14a9.48162416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F55DB1C0-0C08-4483-92FC-097D0EB2FBC9</gtr:id><gtr:title>Can 31P magnetic resonance spectroscopy measurements of changes in experimental tumour metabolism be related to modification of oxygenation status?</gtr:title><gtr:parentPublicationTitle>BJR supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0961-2653</gtr:issn><gtr:outcomeId>pm_14036_136_1290688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06B18D06-F310-4D1E-8EDF-D6BC42295D12</gtr:id><gtr:title>Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e21660c1f7feca2b7fc0738ef9f9cf7"><gtr:id>5e21660c1f7feca2b7fc0738ef9f9cf7</gtr:id><gtr:otherNames>Chaplin DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1983-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_636_6605324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9661911-7356-4BB4-885A-8BACDAC32DEF</gtr:id><gtr:title>Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ece4fc336f814cb4f7184b3ffa4e9ff"><gtr:id>5ece4fc336f814cb4f7184b3ffa4e9ff</gtr:id><gtr:otherNames>Naylor MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1998-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_936_9667963</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AD90D5B-C51C-44FB-B418-066C7EFCD8C7</gtr:id><gtr:title>Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f50e66d5bcc0927516b9fb1f9a94a7f"><gtr:id>5f50e66d5bcc0927516b9fb1f9a94a7f</gtr:id><gtr:otherNames>Dovedi SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5464a463795c14.52284510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49E7917F-26E4-487A-BE58-F0CABEA0CAC8</gtr:id><gtr:title>Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1988-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_336_3166900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAAC26A3-82EC-485D-8487-322532BCD82C</gtr:id><gtr:title>Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f50e66d5bcc0927516b9fb1f9a94a7f"><gtr:id>5f50e66d5bcc0927516b9fb1f9a94a7f</gtr:id><gtr:otherNames>Dovedi SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_14036_26_23086756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99DB25B0-175D-42D9-B814-9244313CBEFF</gtr:id><gtr:title>Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3933f2c467c3c3aa83c6cc0807029139"><gtr:id>3933f2c467c3c3aa83c6cc0807029139</gtr:id><gtr:otherNames>Williams KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>BD3F32F6F96</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>247435DC-BA42-462D-A695-77F26B0D0F33</gtr:id><gtr:title>Monitoring metabolic responses after induction of hypoxia in the KHT tumour using 31P NMR spectroscopy.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5761caa6a3ab1eecf3e9084b41e5e26f"><gtr:id>5761caa6a3ab1eecf3e9084b41e5e26f</gtr:id><gtr:otherNames>Bremner JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1991-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>pm_14036_136_1677995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEF53C22-E08C-4FAB-A1E7-18ABC40FC894</gtr:id><gtr:title>The interaction between radiation and complexes of cis-Pt(II) and Rh(II): studies at the molecular and cellular level.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8adfbdf41897f898a7cf41a14a7b9ac"><gtr:id>d8adfbdf41897f898a7cf41a14a7b9ac</gtr:id><gtr:otherNames>Chibber R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1985-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_336_3876304</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBCBFA55-600A-4633-A722-92563F53A355</gtr:id><gtr:title>The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1986-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_336_3754453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59ECFAB9-A41B-4F3A-A302-02147ADCE28E</gtr:id><gtr:title>Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide).</gtr:title><gtr:parentPublicationTitle>Radiation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1981-01-01</gtr:date><gtr:issn>0033-7587</gtr:issn><gtr:outcomeId>pm_14036_736_7313077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C1AE364-DC0C-47D9-9BC1-3FC048B6E235</gtr:id><gtr:title>Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of enzyme inhibition and medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e25f25b5e6e4e3e42f9e0febbea4b4b"><gtr:id>8e25f25b5e6e4e3e42f9e0febbea4b4b</gtr:id><gtr:otherNames>Gieling RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1475-6366</gtr:issn><gtr:outcomeId>pm_14036_26_23163664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16E215E5-286D-49B4-A481-BC0317FBAA25</gtr:id><gtr:title>A biochemical assessment of the neurotoxicity of the radiosensitizing drug misonidazole in the rat.</gtr:title><gtr:parentPublicationTitle>Clinical toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b061f5c6b8438778a75119b67096a9a3"><gtr:id>b061f5c6b8438778a75119b67096a9a3</gtr:id><gtr:otherNames>Rose GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1981-01-01</gtr:date><gtr:issn>0009-9309</gtr:issn><gtr:outcomeId>pm_14036_636_6277552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3EDD5C5-096A-44FB-B53B-58EA80E99291</gtr:id><gtr:title>Role of nitric oxide in growth of solid tumours: a balancing act.</gtr:title><gtr:parentPublicationTitle>Essays in biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4a9ccb4a0f516a7af15edb98ac85735"><gtr:id>f4a9ccb4a0f516a7af15edb98ac85735</gtr:id><gtr:otherNames>Chinje EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0071-1365</gtr:issn><gtr:outcomeId>pm_14036_936_9493011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62F9AA44-7AAA-4DFA-8C6A-4135A75F8C1E</gtr:id><gtr:title>Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ece4fc336f814cb4f7184b3ffa4e9ff"><gtr:id>5ece4fc336f814cb4f7184b3ffa4e9ff</gtr:id><gtr:otherNames>Naylor MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1995-01-01</gtr:date><gtr:issn>0959-4973</gtr:issn><gtr:outcomeId>pm_14036_736_7795274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5757E116-2035-48A4-A482-0BF7A89F0BA2</gtr:id><gtr:title>Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcea06ec65ff0679c17eaf0561024757"><gtr:id>fcea06ec65ff0679c17eaf0561024757</gtr:id><gtr:otherNames>Nolan KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>8C93D99EC11</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3503B564-FEE8-4292-B2E9-CC0E9E84F068</gtr:id><gtr:title>Relationship between intracellular concentration and radiosensitizing effect of pimonidazole and etanidazole on two human melanoma cell lines.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6d738d6f02ff2e15b17bd98a6474b04"><gtr:id>b6d738d6f02ff2e15b17bd98a6474b04</gtr:id><gtr:otherNames>el Gamoussi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>pm_14036_836_8093465</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CB51466-B148-4D6F-810C-5A268A962D23</gtr:id><gtr:title>Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3933f2c467c3c3aa83c6cc0807029139"><gtr:id>3933f2c467c3c3aa83c6cc0807029139</gtr:id><gtr:otherNames>Williams KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>0956305AB02</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40D5807C-1AE2-4038-85A3-5193825A1725</gtr:id><gtr:title>Construction and characterization of multiple human colon cancer cell lines for inducibly regulated gene expression.</gtr:title><gtr:parentPublicationTitle>Journal of cellular biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a1b5120904d4171c44116a494bfb324"><gtr:id>1a1b5120904d4171c44116a494bfb324</gtr:id><gtr:otherNames>Welman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0730-2312</gtr:issn><gtr:outcomeId>pm_14036_16_15669025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98D9BB20-A4E5-468B-8D79-A00E5AA8785E</gtr:id><gtr:title>Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68cb105cc7153345bde6f30da0f663f1"><gtr:id>68cb105cc7153345bde6f30da0f663f1</gtr:id><gtr:otherNames>Searle EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>5aa91f39c5dfe1.59908994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>607D4A33-A0E3-428C-B22A-56F1B94F1FFB</gtr:id><gtr:title>PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6bbd4623d38f7c1e1af7ae85abd9f19"><gtr:id>f6bbd4623d38f7c1e1af7ae85abd9f19</gtr:id><gtr:otherNames>Xenaki G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>A7F73D68032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>352B9AD0-7CDC-49C1-975A-82A888517A70</gtr:id><gtr:title>Induction of tumour hypoxia by a vasoactive agent. A combined NMR and radiobiological study.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f93ffa820614e1963e816b53c3563c52"><gtr:id>f93ffa820614e1963e816b53c3563c52</gtr:id><gtr:otherNames>Dunn JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>pm_14036_236_2737292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3BCFAE1-F430-4A86-B704-7BD34C4A1500</gtr:id><gtr:title>Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analogues.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5ca56685283bdb73fae9518c0f514b7"><gtr:id>d5ca56685283bdb73fae9518c0f514b7</gtr:id><gtr:otherNames>Walling JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1986-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_336_3755712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C6F7AAD-A6E0-43D6-A9C5-BCD0D05F9E93</gtr:id><gtr:title>Toxicity of nitro compounds toward hypoxic mammalian cells in vitro: dependence on reduction potential.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1980-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>pm_14036_636_6928241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C15F10C-82C9-4EC6-B92F-7B0FB2965A4C</gtr:id><gtr:title>Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1ed274ef4a8f43d1a80f518878b0f06"><gtr:id>a1ed274ef4a8f43d1a80f518878b0f06</gtr:id><gtr:otherNames>Cowen RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_14036_16_14973055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFFB66E3-7171-4131-BEC6-AB5BB445A9AC</gtr:id><gtr:title>Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1989-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>pm_14036_236_2564037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D91480CE-2801-4AF8-995A-184539ECC88F</gtr:id><gtr:title>The CD44-Mediated Uptake of Hyaluronic Acid-Based Carriers in Macrophages.</gtr:title><gtr:parentPublicationTitle>Advanced healthcare materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a10483cf5bb9d5e9441d76dc7fc38324"><gtr:id>a10483cf5bb9d5e9441d76dc7fc38324</gtr:id><gtr:otherNames>Rios de la Rosa JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2192-2640</gtr:issn><gtr:outcomeId>58c82a41d0af60.37283626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85938612-13D3-4D59-86E9-8F56FD085A74</gtr:id><gtr:title>The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy.</gtr:title><gtr:parentPublicationTitle>The British journal of cancer. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56dba8efeb280f62f644d59640315cdb"><gtr:id>56dba8efeb280f62f644d59640315cdb</gtr:id><gtr:otherNames>Dachs GU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0306-9443</gtr:issn><gtr:outcomeId>pm_14036_836_8763864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5E2F458-A5A9-4E5B-8E96-7A32C909BCCD</gtr:id><gtr:title>Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10467f57da5334e2e48ec4bc351ca634"><gtr:id>10467f57da5334e2e48ec4bc351ca634</gtr:id><gtr:otherNames>Lunt SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_14036_16_15930359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5945D859-A00B-4137-8D81-207EB70A4382</gtr:id><gtr:title>The impact of intracellular generation of nitric oxide on the radiation response of human tumor cells.</gtr:title><gtr:parentPublicationTitle>Radiation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fade14a3384de22ad83e51433c35ef62"><gtr:id>fade14a3384de22ad83e51433c35ef62</gtr:id><gtr:otherNames>Singh S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-7587</gtr:issn><gtr:outcomeId>CB2960D7141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65AABC09-82C0-4D2E-81A2-D53EE9290B51</gtr:id><gtr:title>The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37b435222a1293b82bc536d43f062b46"><gtr:id>37b435222a1293b82bc536d43f062b46</gtr:id><gtr:otherNames>Keohane A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1990-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_236_2110815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7616F6A7-704A-46D3-B4FD-E0105F7C4B55</gtr:id><gtr:title>A biochemical neurotoxicity study relating the neurotoxic potential of metronidazole and nitrofurantoin with misonidazole.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b061f5c6b8438778a75119b67096a9a3"><gtr:id>b061f5c6b8438778a75119b67096a9a3</gtr:id><gtr:otherNames>Rose GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_736_7107414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C0573EC-4D61-4F6B-B300-30AAC2970740</gtr:id><gtr:title>The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bae66f1ffefc35438ffca7121f8ed2f8"><gtr:id>bae66f1ffefc35438ffca7121f8ed2f8</gtr:id><gtr:otherNames>Griffiths L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1998-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_936_9845114</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF62D7FC-4CD4-49E2-AA60-1FDB1B7BB5C5</gtr:id><gtr:title>Bioreductive drugs and the selective induction of tumour hypoxia.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5761caa6a3ab1eecf3e9084b41e5e26f"><gtr:id>5761caa6a3ab1eecf3e9084b41e5e26f</gtr:id><gtr:otherNames>Bremner JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1990-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_236_2110814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE1261D0-8032-4466-AA87-CD12687F82ED</gtr:id><gtr:title>In silico identification and biochemical characterization of novel inhibitors of NQO1.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcea06ec65ff0679c17eaf0561024757"><gtr:id>fcea06ec65ff0679c17eaf0561024757</gtr:id><gtr:otherNames>Nolan KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>42EA13AF7DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD7B1677-DEA7-4CB4-B26E-9A3F2CC4ABFF</gtr:id><gtr:title>Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea87cc2fa9fe5edc388a4f4b5afb23ac"><gtr:id>ea87cc2fa9fe5edc388a4f4b5afb23ac</gtr:id><gtr:otherNames>Jaffar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_14036_936_9990467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB2F1BAE-E541-4679-8631-F0A35DC41F1F</gtr:id><gtr:title>Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.</gtr:title><gtr:parentPublicationTitle>Cancer chemotherapy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd725744c5512000223a4a3fd93a1af1"><gtr:id>dd725744c5512000223a4a3fd93a1af1</gtr:id><gtr:otherNames>Braybrooke JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2000-01-01</gtr:date><gtr:issn>0344-5704</gtr:issn><gtr:outcomeId>pm_14036_16_10663625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD56C829-A3A1-4BFB-BFA4-DBD718382FE4</gtr:id><gtr:title>Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1977-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_8036_856238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71D8F91D-EAF3-4DB4-A432-54C573E9353D</gtr:id><gtr:title>Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands.</gtr:title><gtr:parentPublicationTitle>Cancer letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a740708b4cc81b895e9ee74bc436f92"><gtr:id>9a740708b4cc81b895e9ee74bc436f92</gtr:id><gtr:otherNames>Allison SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0304-3835</gtr:issn><gtr:outcomeId>5aa91f3a3d3be2.68585930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>409FF59B-1965-455C-AF26-BB18BF06681C</gtr:id><gtr:title>Proceedings: Inactivation by gamma-rays of Bacillus megaterium spores suspended in aqueous solutions of ethanol, acetone and 1,4-dioxane of widely varying concentrations.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6321c0d5bbe9232ba01ebfd6b1bab61a"><gtr:id>6321c0d5bbe9232ba01ebfd6b1bab61a</gtr:id><gtr:otherNames>Stratford IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1973-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn><gtr:outcomeId>pm_14036_436_4150529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A271B5CB-6700-41C1-9881-2FE9EDB1E03B</gtr:id><gtr:title>2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ece4fc336f814cb4f7184b3ffa4e9ff"><gtr:id>5ece4fc336f814cb4f7184b3ffa4e9ff</gtr:id><gtr:otherNames>Naylor MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14036_936_9240349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52E0C803-6159-47FF-8A41-D3D7541DE3D9</gtr:id><gtr:title>Chemical properties which control selectivity and efficacy of aromatic N-oxide bioreductive drugs.</gtr:title><gtr:parentPublicationTitle>The British journal of cancer. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a416ae18db9997c271b8214251fa6ac4"><gtr:id>a416ae18db9997c271b8214251fa6ac4</gtr:id><gtr:otherNames>Wardman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0306-9443</gtr:issn><gtr:outcomeId>pm_14036_836_8763850</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D88E4F91-62F3-48B4-ABF8-90733C4B44AE</gtr:id><gtr:title>Synthesis and enzymatic evaluation of pyridinium-substituted uracil derivatives as novel inhibitors of thymidine phosphorylase.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcaa98853bea587328b69e1f42cbf6d9"><gtr:id>dcaa98853bea587328b69e1f42cbf6d9</gtr:id><gtr:otherNames>Murray PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>pm_14036_16_11814838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE79EB36-8EC2-48FA-819A-D83845304D05</gtr:id><gtr:title>Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1567bd194f9ae2f653b6c5c6fe08850"><gtr:id>b1567bd194f9ae2f653b6c5c6fe08850</gtr:id><gtr:otherNames>Wood PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>pm_14036_836_8484762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D80C5782-B3D5-4893-9611-3DB2D8C9EED6</gtr:id><gtr:title>Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H mice.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f5841cd112316cc6edb6ac43484418b"><gtr:id>9f5841cd112316cc6edb6ac43484418b</gtr:id><gtr:otherNames>Sutton BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_836_8195030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97877711-EBDE-419E-A1AE-2DE4CFCF805C</gtr:id><gtr:title>Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drug design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ece4fc336f814cb4f7184b3ffa4e9ff"><gtr:id>5ece4fc336f814cb4f7184b3ffa4e9ff</gtr:id><gtr:otherNames>Naylor MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>0266-9536</gtr:issn><gtr:outcomeId>pm_14036_836_8286012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12400F65-6396-4BE2-9E77-6D9AC3AACF94</gtr:id><gtr:title>Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42e8cc10222bb8b3381438e70aaf08b2"><gtr:id>42e8cc10222bb8b3381438e70aaf08b2</gtr:id><gtr:otherNames>Erler JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>pm_14036_16_15024076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04D95932-E418-4259-B51D-77495D86E951</gtr:id><gtr:title>Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4a9ccb4a0f516a7af15edb98ac85735"><gtr:id>f4a9ccb4a0f516a7af15edb98ac85735</gtr:id><gtr:otherNames>Chinje EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_16_10584872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A741DFF2-F3E2-487B-8345-45700164E466</gtr:id><gtr:title>Selective toxicity of TGF-alpha-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d60fa6bf7fbb20b15a40b33e96d6a71f"><gtr:id>d60fa6bf7fbb20b15a40b33e96d6a71f</gtr:id><gtr:otherNames>Kirk J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_836_8198991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99209743-9F31-40AC-ABFF-4E6B37A4000F</gtr:id><gtr:title>A comparison of adriamycin and mAMSA in vitro: cell lethality and SCE studies.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79d39b14c929f20790d749a54d41ad3a"><gtr:id>79d39b14c929f20790d749a54d41ad3a</gtr:id><gtr:otherNames>West C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1981-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_636_6895696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>741E52B4-3C78-45A5-8638-28381B46E834</gtr:id><gtr:title>Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8dcd9a8ca9231cb47c4f3c4de48f137"><gtr:id>b8dcd9a8ca9231cb47c4f3c4de48f137</gtr:id><gtr:otherNames>Harrington KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>tAjLZPK1Agr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5278E2E-D8D1-4B12-A39D-5247944D18E2</gtr:id><gtr:title>Radiosensitization of hypoxic mammalian cells in vitro by some 5-substituted-4-nitroimidazoles.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology and related studies in physics, chemistry, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcc483f70f03c0e556416fadb5a2ffa0"><gtr:id>dcc483f70f03c0e556416fadb5a2ffa0</gtr:id><gtr:otherNames>Adams GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1981-01-01</gtr:date><gtr:issn>0020-7616</gtr:issn><gtr:outcomeId>pm_14036_636_6974144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE937250-9E26-4C9B-B82E-0BCD687F514C</gtr:id><gtr:title>The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4626e7ff8489c78e6788d11e72d651d3"><gtr:id>4626e7ff8489c78e6788d11e72d651d3</gtr:id><gtr:otherNames>Shannon AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>5244E8EF01D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67CA90C5-B477-4650-A1E8-04FA1CDA4D04</gtr:id><gtr:title>Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71505d62178dc25e4da5f5bc99be7e81"><gtr:id>71505d62178dc25e4da5f5bc99be7e81</gtr:id><gtr:otherNames>Cole S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_136_1735694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F17DAB18-2474-4BD2-8D91-2C8DDFDC7A87</gtr:id><gtr:title>In vitro cytotoxic drug sensitivity testing of human tumour xenografts grown as multicellular tumour spheroids.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6843adffd97e5ae681cec1fc27f32bb0"><gtr:id>6843adffd97e5ae681cec1fc27f32bb0</gtr:id><gtr:otherNames>Jones AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1982-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_636_6891260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E96C4561-46C3-49D3-86E8-1758444211E5</gtr:id><gtr:title>Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/782c336ca9b82847685504c7a7765613"><gtr:id>782c336ca9b82847685504c7a7765613</gtr:id><gtr:otherNames>Patterson AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1995-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14036_736_7669579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68945F80-716C-4C83-BF31-E83E92B28B47</gtr:id><gtr:title>Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d60fa6bf7fbb20b15a40b33e96d6a71f"><gtr:id>d60fa6bf7fbb20b15a40b33e96d6a71f</gtr:id><gtr:otherNames>Kirk J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>pm_14036_836_8518026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E502645-FCB2-422B-BFDF-38A5E4AD0FBA</gtr:id><gtr:title>Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3ac7644c3a3118cf6f719e4acf2a07a"><gtr:id>b3ac7644c3a3118cf6f719e4acf2a07a</gtr:id><gtr:otherNames>Atiomo W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>5aa91f3a06d654.08979323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8EBF2E4-E661-4725-8191-0E865BF9712F</gtr:id><gtr:title>Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bd811a5fe1bfd6f608c2b2af9425977"><gtr:id>6bd811a5fe1bfd6f608c2b2af9425977</gtr:id><gtr:otherNames>Ahmed I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1986-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_14036_336_3755711</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500366</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>